



(Please scan this QR code to view the DRHP and this Addendum)



INTEGRIS MEDTECH LIMITED

(FORMERLY KNOWN AS INTEGRIS HEALTH PRIVATE LIMITED)

Our Company was incorporated as 'Integrus Health Private Limited' as a private limited company under Companies Act, 1956 pursuant to certificate of incorporation dated April 25, 2008, issued by Assistant Registrar of Companies, National Capital Territory of Delhi and Haryana at Delhi. Our Company changed its name to 'Integrus Medtech Private Limited', pursuant to which a fresh certificate of incorporation dated June 30, 2025 was issued by the Assistant Registrar of Companies, Central Processing Centre. Further, our Company was converted into a public limited company pursuant to the resolution passed by our Board of Directors on July 16, 2025, and special resolution passed by our Shareholders on August 1, 2025 and the name of our Company was changed to 'Integrus Medtech Limited' and consequently, a fresh certificate of incorporation dated August 8, 2025 was issued by the Assistant Registrar of Companies, Central Processing Centre. For further details in relation to the changes in the name and registered office of our Company, see "History and Certain Corporate Matters" on page 305 of the DRHP.

Registered Office: 1st Floor, Metro Tower LSC, M.O.R Land, New Rajinder Nagar, New Delhi, 110 060 Delhi, India
Corporate Office: 15th Floor, One Horizon Center, Golf Course Road, DLF Phase 5, Sector 43, Gurgaon 122002, Haryana, India
Tel: +91 124 4673710; **Website:** www.integrismedtech.com; **Contact person:** Darpan Batra, Group General Counsel, Company Secretary and Compliance Officer
E-mail: investors@integrismedtech.com; **Corporate Identity Number:** U85110DL2008PLC177230

NOTICE TO INVESTORS					
ADDENDUM TO THE DRAFT RED HERRING PROSPECTUS DATED OCTOBER 9, 2025 (THE "ADDENDUM" AND SUCH DRAFT RED HERRING PROSPECTUS, THE "DRAFT RED HERRING PROSPECTUS" OR THE "DRHP")					
PROMOTERS OF OUR COMPANY: EVERCURE HOLDINGS PTE. LTD., MEDICORE HOLDINGS PTE. LTD., GURMIT SINGH CHUGH AND PUNITA SHARMA					
INITIAL PUBLIC OFFERING OF UP TO [•] EQUITY SHARES OF FACE VALUE OF ₹1 EACH ("EQUITY SHARES") OF INTEGRIS MEDTECH LIMITED (FORMERLY KNOWN AS INTEGRIS HEALTH PRIVATE LIMITED) (OUR "COMPANY" OR THE "COMPANY") FOR CASH AT A PRICE OF ₹[•] PER EQUITY SHARE (INCLUDING A PREMIUM OF ₹[•] PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING UP TO ₹[•] MILLION (THE "OFFER") COMPRISING A FRESH ISSUE OF UP TO [•] EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹6,000.00 MILLION (THE "FRESH ISSUE") AND AN OFFER FOR SALE (THE "OFFER FOR SALE") OF UP TO 10,837,266 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY EVERCURE HOLDINGS PTE. LTD., (THE "PROMOTER SELLING SHAREHOLDER" AND SUCH SHARES, THE "OFFERED SHARES").					
THE FACE VALUE OF EQUITY SHARES IS ₹1 EACH. THE OFFER PRICE IS [•] TIMES THE FACE VALUE OF THE EQUITY SHARES. THE PRICE BAND AND THE MINIMUM BID LOT SHALL BE DECIDED BY OUR COMPANY, IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGERS, AND WILL BE ADVERTISED IN ALL EDITIONS OF FINANCIAL EXPRESS, AN ENGLISH NATIONAL DAILY NEWSPAPER AND ALL EDITIONS OF JANSATTA, A HINDI NATIONAL DAILY NEWSPAPER (HINDI ALSO BEING THE REGIONAL LANGUAGE OF DELHI, WHERE OUR REGISTERED OFFICE IS LOCATED) EACH WITH WIDE CIRCULATION, AT LEAST TWO WORKING DAYS PRIOR TO THE BID/OFFER OPENING DATE AND SHALL BE MADE AVAILABLE TO THE STOCK EXCHANGES FOR THE PURPOSE OF UPLOADING ON THEIR RESPECTIVE WEBSITES IN ACCORDANCE WITH THE SEBI ICDR REGULATIONS.					
This Addendum is in reference to the DRHP filed with the Securities and Exchange Board of India ("SEBI") and the Stock Exchanges. In this regard, potential investors should note that in accordance with the SEBI ICDR Regulations and the guidance provided by SEBI pursuant to its email dated April 13, 2026 read with its email dated October 12, 2026 to the Association of Investment Bankers of India permitting issuers to increase or decrease the fresh issue size by up to 50%, without re-filing the draft red herring prospectus for all initial public offerings opening on or before March 31, 2027 (the "SEBI Communication"), and pursuant to Board resolution dated October 19, 2026, our Company has decided to reduce the size of the fresh issue in the Offer from INR 9,250 million as disclosed in the DRHP to INR 6,000 million (i.e. within the permissible limit of up to 50%) due to evolving market dynamics resulting from heightened volatility arising from external geopolitical developments. Further, our Company has received (i) letters from Gurmit Singh Chugh and Punita Sharma, each dated October 18, 2026, who had earlier consented to participate as selling shareholders in the Offer for Sale, informing our Company of their decision to withdraw the offer of their portion of the Offered Shares in the Offer, and (ii) consent letter dated October 19, 2026 from Evercure Holdings Pte. Ltd. informing our Company of its decision to decrease its portion of the Offered Shares in the Offer for Sale to up to 10,837,266 Equity Shares. Accordingly, the Offer size has been revised and disclosed through this Addendum. All references to the Fresh Issue size, Offer for Sale and the overall Offer size in the DRHP shall be revised and modified at all applicable places in the Red Herring Prospectus, the Abridged Prospectus, and Prospectus, as applicable.					
Potential investors may note that in order to assist the investors to get a complete understanding of the updated information, the sections titled "The Offer" and "Objects of the Offer" beginning on pages 80 and 116 respectively, of the DRHP, have been appropriately updated only to reflect changes related to the updated Fresh Issue size, Offer for Sale and the Offer size and included in this Addendum to reflect, <i>inter alia</i> , the above modifications.					
Accordingly, the required updates and amendments to the portions of the cover page and sections titled "Definitions and Abbreviations", "The Offer", "Capital Structure", "Objects of the Offer" and "Offer Structure" beginning on pages 1, 80, 98, 116 and 571 respectively, of the DRHP, will be updated in the Red Herring Prospectus, Abridged Prospectus, and Prospectus, as applicable.					
The changes conveyed by way of this Addendum are to be read in conjunction with the DRHP and, accordingly, the corresponding references in the DRHP stand updated pursuant to this Addendum. The information in this Addendum supplements and updates the information in the DRHP, as applicable, and accordingly henceforth any reference to the DRHP shall be a reference to the DRHP read with this Addendum. However, this Addendum does not purport to, nor does it, reflect all the changes that have occurred from the date of filing of the DRHP and till the date of this Addendum. Accordingly, this Addendum does not include all the changes and/or updates that will be included in the Red Herring Prospectus and/or the Abridged Prospectus and/or the Prospectus as and when filed with the Registrar of Companies, National Capital Territory of Delhi – II at Delhi ("RoC"), the SEBI and the Stock Exchanges. Please note that the information included in the DRHP will be suitably updated, including to the extent stated/ updated by way of this Addendum, as may be applicable, in the Red Herring Prospectus, the Abridged Prospectus, and the Prospectus. Investors should not rely on the DRHP or this Addendum for any investment decision, and should read the Red Herring Prospectus, as and when it is filed with the RoC, SEBI and the Stock Exchanges before making an investment decision with respect to the Offer.					
This Addendum which has been filed with SEBI and the Stock Exchanges and shall be available on the website of SEBI at www.sebi.gov.in, the website of Stock Exchanges at www.nseindia.com and www.bseindia.com, the website of our Company at www.integrismedtech.com and the websites of the Book Running Lead Managers, namely, ICICI Securities Limited, Axis Capital Limited, Citigroup Global Markets India Private Limited, and IIFL Capital Services Limited (formerly known as IIFL Securities Limited) on www.icicisecurities.com, www.axiscapital.co.in, www.citigroup.com/global/about-us/global-presence/india/disclaimer, and www.iiflcapital.com, respectively. Unless stated otherwise, all references to page numbers in this Addendum are to the page numbers of the DRHP. All capitalized terms used in this Addendum shall, unless the context otherwise requires, have the meanings ascribed to them in the DRHP.					
Place: Gurugram, India Date: October 19, 2026			For Integrus Medtech Limited On behalf of the Board of Directors Sd/- Darpan Batra Group General Counsel, Company Secretary and Compliance Officer		
BOOK RUNNING LEAD MANAGERS					REGISTRAR TO THE OFFER
ICICI Securities Limited ICICI Venture House Appasaheb Marathe Marg Prabhadevi, Mumbai 400 025 Maharashtra, India Tel: +91 22 6807 7100 Email: integrisspo@icicisecurities.com Website: www.icicisecurities.com Investor Grievance ID: customercare@icicisecurities.com Contact person: Tanya Tiwari/ Ramesh Vaswana SEBI registration No.: INM000011179	Axis Capital Limited 1st Floor, Axis House Pandurang Budhkar Marg, Worli Mumbai 400 025 Maharashtra, India Tel: + 91 22 4325 2183 E-mail: integris.ipo@axiscap.in complaints@axiscap.in Investor Grievance ID: complaints@axiscap.in Contact person: Tosit Agarwal SEBI Registration No.: INM000012029	Citigroup Global Markets India Private Limited 1202, 12 th Floor, First International Financial Centre (FIFC) G-Block, Bandra Kurla Complex, Bandra East Mumbai 400 098 Maharashtra, India Tel: +91 22 6175 9999 E-mail: integrismedtech.ipo@citigroup.com Investor Grievance ID: investors.cgmib@citigroup.com Website: https://www.citigroup.com/global/about-us/global-presence/india/disclaimer Contact person: Adarsh Agarwal SEBI Registration No.: INM000010718	IIFL Capital Services Limited (formerly known as IIFL Securities Limited) 24th Floor, One Lodha Place Senapati Bapat Marg, Lower Parel (West) Mumbai 400 013 Maharashtra, India Tel: +91 22 4646 4728 E-mail: integris.ipo@iiflcap.com Investor Grievance ID: ig_ib@iiflcap.com Website: www.iiflcapital.com Contact person: Yogesh Malpani / Pawan Kumar Jain SEBI Registration No.: INM000010940	KFin Technologies Limited Selenium Tower B, Plot No. 31 and 32 Financial District, Nanakramguda Serilingampally Hyderabad - 500 032 Telangana, India Tel: +91 406716 2222/ 18003094001 E-mail: integris.ipo@kfintech.com Investor Grievance ID: einward.ris@kfintech.com Website: www.kfintech.com Contact person: Williams R SEBI Registration No.: INR000000221	
BID/OFFER PERIOD					
ANCHOR INVESTOR BID/OFFER PERIOD	[•]	BID/OFFER OPENS ON	[•]	BID/OFFER CLOSES ON**	[•]

* Our Company may in consultation with the Book Running Lead Managers, consider participation by Anchor Investors in accordance with the SEBI ICDR Regulations. The Anchor Investor Bid/Offer Period shall be one Working Day prior to the Bid/Offer Opening Date.

** Our Company, in consultation with the Book Running Lead Managers, may consider closing the Bid/Offer Period for QIBs one Working Day prior to the Bid/Offer Closing Date in accordance with the SEBI ICDR Regulations.

Integrus Medtech Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares and has filed the DRHP dated October 9, 2025 with SEBI and the Stock Exchanges. The DRHP is available on the website of SEBI at www.sebi.gov.in, the website of Stock Exchanges at www.nseindia.com and www.bseindia.com, the website of our Company at www.integrusmedtech.com and the websites of the Book Running Lead Managers, namely, ICICI Securities Limited, Axis Capital Limited, Citigroup Global Markets India Private Limited, and IIFL Capital Services Limited (formerly known as IIFL Securities Limited) on www.icicisecurities.com, www.axiscapital.co.in, www.citigroup.com/global/about-us/global-presence/india/disclaimer, and www.iiflcapital.com, respectively. Potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risks, please see the section entitled "Risk Factors" on page 34 of the DRHP and the details set out in the RHP, when filed. Potential investors should not rely on the DRHP filed with SEBI and Stock Exchanges and should rely on the RHP, for making any investment decision.

This announcement does not constitute an invitation or offer of securities for sale in any jurisdiction. The Equity Shares offered in the Offer have not been and will not be registered under the United States Securities Act of 1933, as amended ("**U.S. Securities Act**") or any state securities laws in the United States, and unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold outside the United States in 'offshore transactions' as defined in and in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdictions where such offers and sales are made. The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Bids may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.

TABLE OF CONTENTS

THE OFFER	4
OBJECTS OF THE OFFER.....	6
DECLARATION	38

THE OFFER

The following table summarizes the Offer details:

Offer of Equity Shares ⁽¹⁾⁽²⁾	Up to [●] Equity Shares of face value ₹1 each, aggregating up to ₹[●] million
of which	
Fresh Issue ⁽¹⁾	Up to [●] Equity Shares of face value ₹1 each, aggregating up to ₹6,000.00 million
Offer for Sale ⁽²⁾	Up to 10,837,266 Equity Shares of face value ₹1 each, aggregating up to ₹[●] million
<i>The Offer consists of:</i>	
A) QIB Portion⁽³⁾⁽⁴⁾	Not less than [●] Equity Shares of face value ₹1 each, aggregating up to ₹[●] million
<i>of which:</i>	
Anchor Investor Portion	Up to [●] Equity Shares of face value ₹1 each
<i>of which 40% of the Anchor Investor Portion shall be reserved in the following manner:</i>	
- 33.33% of the Anchor Investor Portion shall be reserved for allocation to domestic Mutual Funds	Up to [●] Equity Shares of face value of ₹1 each
- 6.67% of the Anchor Investor Portion shall be reserved for allocation to Life Insurance Companies and Pension Funds	Up to [●] Equity Shares of face value of ₹1 each
Net QIB Portion (assuming Anchor Investor Portion is fully subscribed)	[●] Equity Shares of face value ₹1 each
<i>of which:</i>	
Available for allocation to Mutual Funds only (5% of the Net QIB Portion)	[●] Equity Shares of face value ₹1 each
Balance of QIB Portion for all QIBs including Mutual Funds	[●] Equity Shares of face value ₹1 each
B) Non-Institutional Portion⁽³⁾⁽⁵⁾	Not more than [●] Equity Shares of face value ₹1 each, aggregating up to ₹[●] million
<i>of which:</i>	
One-third of the Non-Institutional Portion available for allocation to Bidders with an application size of more than ₹0.20 million and up to ₹1.00 million	[●] Equity Shares of face value ₹1 each
Two-thirds of the Non-Institutional Portion available for allocation to Bidders with an application size of more than ₹1.00 million	[●] Equity Shares of face value ₹1 each
C) Retail Portion⁽³⁾	Not more than [●] Equity shares of face value ₹1 each, aggregating up to ₹[●] million
Pre-Offer and post-Offer Equity Shares	
Equity Shares outstanding prior to the Offer (as on the date of this Draft Red Herring Prospectus)	108,338,049 Equity Shares of face value ₹1 each
Equity Shares outstanding after the Offer	[●] Equity Shares of face value ₹1 each
Use of Net Proceeds of the Offer	See “Objects of the Offer” beginning on page [●] for details regarding the use of Net Proceeds

- (1) Our Board has authorized the Offer pursuant to its resolution dated September 22, 2025, read with the resolution dated October 19, 2026, and the Fresh Issue has been authorised by our Shareholders, pursuant to their special resolution dated September 29, 2025.
- (2) Our Board has pursuant to its resolution dated October 19, 2026 taken on record the consent of Promoter Selling Shareholder to participate in the Offer for Sale in relation to the Offered Shares. The Promoter Selling Shareholder has authorised its participation in the Offer for Sale for the Offered Shares, as set out below:

S. No.	Promoter Selling Shareholder	Number of Offered Shares*	Aggregate proceeds from the Offered Shares	Date of board resolution/ corporate authorisation	Date of consent letter
1.	Evercre Holdings Pte. Ltd.	Up to 10,837,266 Equity Shares of face value of ₹1 each	Up to ₹[●] million	September 29, 2025	October 19, 2026

* The Promoter Selling Shareholder, has confirmed its eligibility to participate in the Offer for Sale in accordance with Regulation 8 of the SEBI ICDR Regulations. Further, the Promoter Selling Shareholder confirms that the Offered Shares will be offered for sale in the Offer in accordance with Regulation 8A of the SEBI ICDR Regulations, to the extent applicable to the Promoter Selling Shareholder. For details of authorisations for the Offer for Sale, see “Other Regulatory and Statutory Disclosures – Authority for the Offer” on page [●].

- (3) Subject to valid Bids being received at or above the Offer Price, under-subscription, if any, in any category except the QIB Portion, would be allowed to be met with spill-over from any other category or combination of categories of Bidders at the discretion of our Company, in consultation with the Book

Running Lead Managers, and the Designated Stock Exchange, subject to applicable laws. Under-subscription, if any, in the QIB Portion (excluding the Anchor Investor Portion) will not be allowed to be met with spill-over from other categories or a combination of categories.

- (4) *Our Company, in consultation with the Book Running Lead Managers may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis of which 40% of the Anchor Investor Portion shall be reserved in the following manner: (a) 33.33% shall be reserved for domestic Mutual Funds; and (b) 6.67% shall be reserved for Life Insurance Companies and Pension Funds, subject to valid bids being received from domestic Mutual Funds, Life Insurance Companies and Pension Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription or non-Allotment in the Anchor Investor Portion, the remaining Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders (other than Anchor Investors), including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than [●] Equity Shares of face value ₹1 each, the balance Equity Shares available for allotment in the Mutual Fund Portion will be added to the Net QIB Portion and allocated proportionately to the QIB Bidders (other than Anchor Investors) in proportion to their Bids. For details, see “Offer Procedure” beginning on page [●]. Allocation to all categories shall be made in accordance with the SEBI ICDR Regulations.*
- (5) *The Equity Shares available for allocation to Non-Institutional Bidders under the Non-Institutional Portion, shall be subject to the following: (i) one-third of the portion available to Non-Institutional Bidders shall be reserved for applicants with an application size of more than ₹0.20 million and up to ₹1.00 million, and (ii) two-third of the portion available to Non-Institutional Bidders shall be reserved for applicants with application size of more than ₹1.00 million, provided that the unsubscribed portion in either of the aforementioned sub-categories may be allocated to applicants in the other sub-category of Non-Institutional Bidders. The allotment to each Non-Institutional Bidder shall not be less than the minimum application size, subject to the availability of Equity Shares in the Non-Institutional Portion, and the remaining Equity Shares, if any, shall be allotted on a proportionate basis.*

Allocation to Bidders in all categories except the Anchor Investor Portion, Non-Institutional Portion and the Retail Portion, if any, shall be made on a proportionate basis subject to valid Bids received at or above the Offer Price. The allocation to each of the RIBs shall not be less than the minimum Bid Lot, subject to availability of Equity Shares in the Retail Portion and the remaining available Equity Shares, if any, shall be allocated on a proportionate basis. Allocation to Anchor Investors shall be on a discretionary basis in accordance with the SEBI ICDR Regulations. For further details, see “Offer Procedure” beginning on page [●].

For details of the terms of the Offer, see “Terms of the Offer” beginning on page [●].

OBJECTS OF THE OFFER

Offer comprises the Fresh Issue of up to [●] Equity Shares of face value ₹1 each aggregating up to ₹ 6,000.00 million and the Offer for Sale of up to 10,837,266 Equity Shares of face value ₹1 each aggregating up to ₹ [●] million, cumulatively aggregating up to ₹ [●] million.

Offer for Sale

The object of the Offer for Sale is to allow the Promoter Selling Shareholder to sell an aggregate of up to 10,837,266 Equity Shares having face value of ₹ 1 each aggregating up to ₹ [●] million held by them. The Promoter Selling Shareholder shall be entitled to the proceeds of the Offer for Sale, after deducting its proportion of the Offer-related expenses and the relevant taxes thereon, in accordance with the terms of the Offer Agreement. For further details, see “ - Offer expenses ” on page [●]. Our Company will not receive any proceeds from the Offer for Sale and the proceeds received from the Offer for Sale will not form part of the Net Proceeds. For further details of the Offer for Sale, see “The Offer” on page [●].

The Promoter Selling Shareholder has authorised its participation in the Offer for Sale to the extent of the Offered Shares, pursuant to their respective consent letters, as set out below. For details, see “The Offer” on page [●].

S. No.	Promoter Selling Shareholder	Number of Offered Shares	Aggregate proceeds from the Offered Shares*	Date of board resolution/ corporate authorisation	Date of consent letter
1.	Evercure Holdings Pte. Ltd.	Up to 10,837,266 Equity Shares of face value of ₹1 each	Up to ₹[●] million	September 29, 2025	October 19, 2026

*To be determined upon finalisation of the Offer Price and updated in the Prospectus prior to filing with the RoC.

Objects of the Fresh Issue

Our Company proposes to utilize the Net Proceeds from the Fresh Issue towards funding the following objects:

1. Repayment/ prepayment, in full or in part, of certain outstanding borrowings, interest accrued and prepayment penalties, as applicable, availed by:
 - a. Our wholly-owned Subsidiaries, namely, Translumina Therapeutics Private Limited (“**Translumina Therapeutics**”) and Transheath Private Limited (“**Transheath**”) ; and
 - b. Our step-down Subsidiaries, namely, CPC Diagnostics Private Limited, Chemopharm Sdn. Bhd. and Research Instruments Pte. Ltd.
2. General corporate purposes.

(collectively, the “**Objects**”, and individually, each an “**Object**”).

Further, our Company expects to receive the benefits of listing of the Equity Shares on the Stock Exchanges, including enhancement of our Company’s brand name and creation of a public market for our Equity Shares in India.

The main objects and objects incidental and ancillary to the main objects set out in the Memorandum of Association enable us: (i) to undertake our existing business activities; and (ii) to undertake the activities for which the funds are being raised by us in the Fresh Issue and are proposed to be funded from the Net Proceeds.

Net Proceeds

After deducting our Company’s share of the Offer related expenses from the Gross Proceeds received pursuant to the Fresh Issue, we estimate the net proceeds to be ₹[●] million (“**Net Proceeds**”), as set out in the table below:

(in ₹ million)	
Particulars	Estimated amount
Gross Proceeds of the Fresh Issue*	6,000.00
(Less) Offer related expenses in relation to the Fresh Issue^	[●]*
Net Proceeds*	[●]*

*To be determined upon finalisation of the Offer Price and updated in the Prospectus prior to filing with the RoC.

^ For details of the expenses related to the Offer, see “ - Offer Expenses ” on page [●]

Requirement of funds and utilization of Net Proceeds

The Net Proceeds are proposed to be utilized in accordance with the details set out in the table below:

Sr. No.	Particulars	Amount
		(₹ million)
1.	Repayment/ prepayment, in full or in part, of certain outstanding borrowings, interest accrued and prepayment penalties, as applicable, availed by:	5,098.51
a.	Our wholly-owned Subsidiaries, namely, Translumina Therapeutics and Transhealth	938.74
b.	Our step-down Subsidiaries, namely, CPC Diagnostics Private Limited, Chemopharm Sdn. Bhd.. and Research Instruments Pte. Ltd.	4,159.77
2.	General corporate purposes ^{^*}	[●]
	Net Proceeds[*]	[●]

[^] The amount to be utilised for general corporate purposes shall not exceed 25% of the Gross Proceeds.

^{*} To be determined upon finalisation of the Offer Price and Offer Expenses and shall be updated in the Prospectus prior to filing with the RoC.

Proposed schedule of implementation and deployment of Net Proceeds

We propose to deploy the Net Proceeds towards the Objects in accordance with the estimated schedule of implementation and deployment of funds set forth in the table below:

(in ₹ million)

Particulars	Estimated amount proposed to be utilised from Net Proceeds	Estimated schedule of deployment of Net Proceeds in Fiscal 2027
Repayment/ prepayment, in full or in part, of certain outstanding borrowings, interest accrued and prepayment penalties, as applicable, availed by:	5,098.51	5,098.51
a. Our wholly-owned Subsidiaries, namely, Translumina Therapeutics and Transhealth	938.74	938.74
b. Our step-down Subsidiaries, namely, CPC Diagnostics Private Limited, Chemopharm Sdn. Bhd.. and Research Instruments Pte. Ltd.	4,159.77	4,159.77
General corporate purposes ⁽¹⁾⁽²⁾	[●]	[●]
Total⁽²⁾	[●]	[●]

⁽¹⁾ The amount to be utilised for general corporate purposes shall not exceed 25% of the Gross Proceeds.

⁽²⁾ To be finalized upon determination of the Offer Price and Offer Expenses and shall be updated in the Prospectus prior to filing with the RoC.

Pursuant to a resolution passed by the Board dated October 19, 2026, our Company has approved the utilisation of the Net Proceeds for the Object and the schedule of deployment and implementation, as set out above.

The above fund requirements are based on our current business plans, market trends, prevailing interest rates, management estimates and other external commercial and technical factors which are subject to change in the future. These are based on current conditions and are subject to revisions due to changes in costs, our financial condition, our business operations, growth strategies or external circumstances which may not be in our control, including evolutions in market trends.

Our fund requirements described herein have not been appraised by any bank or financial institution or other independent agency. For further details, please see “Risk Factors – Any variation in the utilisation of the Net Proceeds would be subject to certain compliance requirements, including prior Shareholders’ approval. Further, our funding requirements and deployment of the Net Proceeds of the Offer are based on management estimates and have not been independently appraised. Our management will have broad discretion over the use of the Net Proceeds” on page [●]. However, the actual deployment of funds will depend on a number of factors, including the timing of completion of the Offer, market conditions, our Board’s analysis of economic trends and business requirements, ability to identify and consummate proposed investment and acquisition, competitive landscape, as well as general factors affecting our results of operations and financial condition.

This may entail rescheduling or revising the proposed utilization of the Net Proceeds, (including preponing the deployment of Net Proceeds), the implementation and deployment schedule provided above and our funding requirements, including the expenditure for a particular purpose, at the discretion of our management, subject to compliance with the applicable requirements under the Companies Act, the SEBI ICDR Regulations, the SEBI Listing Regulations and other applicable law. In the event that the estimated utilization of the Net Proceeds in a scheduled Fiscal is not completely met, including due to the reasons stated above, the same shall be utilized in the next Fiscal as may be determined by our Company, in accordance with applicable laws.

We may have to revise our funding requirements and deployment on account of a variety of factors such as our financial and

market condition, increase in the rate of taxation or change in the rate of currency exchange, our management's analysis of economic trends and our business requirements, fund requirements in the operations of our Subsidiaries, inorganic and geographic expansion opportunities, our business and growth strategies, competitive landscape, general factors affecting our results of operations, financial condition and access to capital and other external factors such as changes in the business environment or regulatory climate and interest or exchange rate fluctuations, which may not be within the control of our management. This may entail revising the funding requirement for a particular Object or increasing or decreasing the amounts earmarked towards any of the aforementioned Objects at the discretion of our management, subject to compliance with applicable law.

In case of any surplus amount after utilization of the Net Proceeds towards the aforementioned Object, we may use such surplus amount towards general corporate purposes, subject to applicable laws to the extent that the total amount to be utilized towards general corporate purposes will not exceed 25% of the Gross Proceeds in accordance with the SEBI ICDR Regulations. Further, in case of a shortfall in meeting the aforementioned Objects, we may explore a range of alternate funding options including availing future debt from lenders. We believe that such alternate funding arrangements would be available to fund any such shortfalls.

For further information on factors that may affect our internal management estimates for the deployment of funds towards the Objects, see *"Risk Factors - Any variation in the utilisation of the Net Proceeds would be subject to certain compliance requirements, including prior Shareholders' approval. Further, our funding requirements and deployment of the Net Proceeds of the Offer are based on management estimates and have not been independently appraised. Our management will have broad discretion over the use of the Net Proceeds"* on page [●].

Means of finance

The fund-requirements for the Objects are proposed to be met entirely from the Net Proceeds. Accordingly, our Company confirms that there is no requirement to make firm arrangements of finance through verifiable means towards at least 75% of the stated means of finance, excluding the amount to be raised through the Fresh Issue as required under Regulation 7(1)(e) the SEBI ICDR Regulations.

Details of the Objects

Repayment/ prepayment, in full or in part, of certain outstanding borrowings, interest accrued and prepayment penalties, as applicable, availed by (a) wholly-owned Subsidiaries, namely, Translumina Therapeutics and Transhealth (b) step-down Subsidiaries, namely, CPC Diagnostics Private Limited, Chemopharm Sdn. Bhd. and Research Instruments Pte. Ltd.

The following wholly-owned Subsidiaries have entered into various financial arrangements, including borrowings in the form of term loans, working capital facilities with banks and financial institutions:

1. Translumina Therapeutics, an Indian company (wholly owned by our Company)
2. Transhealth, an Indian company (wholly owned by our Company); and
(for the purposes of this Object, collectively referred to as **"Wholly Owned Subsidiaries"**),

Further, the following step-down Subsidiaries have entered into various financial arrangements, including borrowings in the form of term loans, working capital facilities with banks and financial institutions:

1. CPC Diagnostics Private Limited, an Indian company (64.61% held by Everlife Holdings Pte. Ltd. and 10.62 % held by our Company);
2. Chemopharm Sdn. Bhd., a Malaysian company (100% held by Everlife Holdings Pte. Ltd.); and
3. Research Instruments Pte. Ltd., a Singapore-based company (wholly-owned by Chemopharm Sdn. Bhd.) (for the purposes of this Object, collectively referred to as **"Step-Down Subsidiaries"**)

As of August 31, 2026 we had total borrowings of ₹8,627.64 million on a consolidated basis. For further details, see *"Financial Indebtedness"* beginning on page [●].

Our Company proposes to utilise an estimated amount of ₹938.74 million and ₹4,159.77 million, respectively, aggregating to ₹5,098.51 million, from the Net Proceeds towards prepayment or repayment, in full or in part, of all or a portion of certain outstanding borrowings (including interest accrued and prepayment penalties as applicable), availed by our Wholly-Owned Subsidiaries and our Step-Down Subsidiaries (such loans, **"Identified Loans"**), respectively, which constitutes 10.88% and 48.21%, respectively, of our total outstanding borrowings, on a consolidated basis, as of August 31, 2026. Pursuant to the terms of the borrowing arrangements entered into by Wholly-Owned Subsidiaries and our Step-Down Subsidiaries, prepayment of certain indebtedness may attract prepayment charges as prescribed by the respective lender. Such prepayment charges, as applicable, and the accrued interest on our outstanding borrowings will also be funded out of the Net Proceeds. Our Company

confirms that it will not utilize more than 50% of the proceeds of the Fresh Issue towards repayment/ prepayment of term loan facilities utilised towards capital expenditure.

Further, we intend to utilise the entire amount earmarked for this object in Fiscals 2027 in relation to repayment / prepayment the Identified Loans. In relation to our Wholly-Owned Subsidiaries and our Step-Down Subsidiaries, such deployment of Net Proceeds is being undertaken in Fiscals 2027 and will be subject to the timelines of infusion of funds by our Company in the Wholly-Owned Subsidiaries and our Step-down Subsidiaries and the subsequent repayment/ prepayment of outstanding borrowings by such Wholly-Owned Subsidiaries and Step-Down Subsidiaries, post infusion of such funds. For further details, see “- *Proposed schedule of implementation and deployment of Net Proceeds*” on page [●].

The repayment/ prepayment will help our Wholly-Owned Subsidiaries and our Step-Down Subsidiaries, reduce their respective outstanding indebtedness, assist us in reducing our interest outflow and enable utilisation of some additional amount from our internal accruals for further investment in business growth and expansion.

In addition, we believe that our debt-equity ratio will improve, which will enable us to raise additional funds/ capital at competitive rates in the future to fund potential business development opportunities and plans to grow and expand our business in the future. The following table set forth details of the Identified Loans availed by our Wholly-Owned Subsidiaries and our Step-Down Subsidiaries, as applicable, which are outstanding as on June 30, 2025 and August 31, 2026 which we will repay/ prepay, all or a portion of, from the Net Proceeds

Utilisation of loans by our Wholly-Owned Subsidiaries, namely, Translumina Therapeutics and Transhealth

Sr. No.	Name of the lender	Name of the borrower	Date of sanction letter / facility agreement	Loan disbursement dates(s)	Nature of borrowing	Amount sanctioned/ availed as on June 30, 2026 (₹ in million)	Amount sanctioned/ availed as on August 31, 2026 (₹ in million)*	Amount outstanding as on June 30, 2026 (₹ in million)	Amount outstanding as on August 31, 2026 (₹ in million)*	Tenor/ Repayment schedule	Interest rate as at June 30, 2026 (in %)	Interest rate as at August 31, 2026 (in %)*	Purpose for which the loan was availed ⁽¹⁾ and original purpose of the loan (in case subsequent loans are for refinancing / reimbursement / takeover of existing loans, etc.	Prepayment clause (if any)
1.	Citibank, N.A. ⁽¹⁾	Translumina Therapeutics Private Limited	Letter dated January 2, 2026 [^]	N.A. ⁽²⁾	Cash credit	600.00 ⁽¹⁾	600.00*	491.90 ⁽¹⁾	431.22*	Maximum 12 months from the date of the sanction letter	Average interest rate is 9.50% ⁽¹⁾	Average interest rate is 8.66%*	Financing its Working capital requirements	Up to 2% per annum on the prepaid amount in case of loan prepayment (for the period computed as difference between the date of prepayment to the maturity date or next reset date whichever is earlier). However, in respect of Facilities with floating rate interest, no such charges will be payable if a prepayment of such Facility is made on an Interest Reset Date
2.	HDFC Bank ⁽¹⁾	Translumina Therapeutics Private	March 17, 2026	N.A. ⁽²⁾	Cash Credit	500.00 ⁽¹⁾	505.50*	141.59 ⁽¹⁾	116.87*	Valid up to February 02, 2027	Spread of 3% with 3M Repo, i.e., 8.25 ⁽¹⁾	Interest Rate Linked*	Business purpose for purchasing raw materials,	Upto 4% of loan Principal outstanding

Sr. No.	Name of the lender	Name of the borrower	Date of sanction letter / facility agreement	Loan disbursement dates(s)	Nature of borrowing	Amount sanctioned/ availed as on June 30, 2026 (₹ in million)	Amount sanctioned/ availed as on August 31, 2026 (₹ in million)*	Amount outstanding as on June 30, 2026 (₹ in million)	Amount outstanding as on August 31, 2026 (₹ in million)*	Tenor/ Repayment schedule	Interest rate as at June 30, 2026 (in %)	Interest rate as at August 31, 2026 (in %)*	Purpose for which the loan was availed ⁽¹⁾ and original purpose of the loan (in case subsequent loans are for refinancing / reimbursement / takeover of existing loans, etc.	Prepayment clause (if any)
		Limited		N.A. ⁽²⁾	Buyer Credit			260.63 ⁽¹⁾	288.88*		EURIBOR Plus Spread 1.7 % i.e. 4.10% ⁽¹⁾	EURIBOR Plus Spread 1.7 % i.e. 4.42%*	making payments to vendors and service payments	for Term loan and 4% of the sanctioned amount for Working Capital Facility (plus taxes). Micro and Small Enterprises, as per BCSBI guidelines, prepayment charges will not be levied if the said borrower is prepaying the floating rate loans and for fixed rates loans upto a cap of 50 lakhs to reduce the business liabilities. Bank reserves the right to enquire or ask the documentary proof Of source of funds for closure request of loans.

Sr. No.	Name of the lender	Name of the borrower	Date of sanction letter / facility agreement	Loan disbursement dates(s)	Nature of borrowing	Amount sanctioned/ availed as on June 30, 2026 (₹ in million)	Amount sanctioned/ availed as on August 31, 2026 (₹ in million)*	Amount outstanding as on June 30, 2026 (₹ in million)	Amount outstanding as on August 31, 2026 (₹ in million)*	Tenor/ Repayment schedule	Interest rate as at June 30, 2026 (in %)	Interest rate as at August 31, 2026 (in %)*	Purpose for which the loan was availed ⁽¹⁾ and original purpose of the loan (in case subsequent loans are for refinancing / reimbursement / takeover of existing loans, etc.	Prepayment clause (if any)
3.	ICICI Bank ⁽¹⁾	Translumina Therapeutics Private Limited	January 24, 2025 read with the letter dated January 9, 2026	N.A. ⁽²⁾	Cash Credit	100.00 ⁽¹⁾	100.00*	61.36 ⁽¹⁾	82.54*	Valid up to December 22, 2026	Interest rate is repo rate of 5.25% and spread of 3.6% i.e. 8.85% ⁽¹⁾	Interest rate is repo rate of 5.25% and spread of 3.6% i.e. 8.85%*	Working capital facilities	-
4.	ICICI Bank ⁽¹⁾	Transhealth Private Limited	January 28, 2025, read with the letter dated January 13, 2026	N.A. ⁽²⁾	Cash Credit	20.20 ⁽¹⁾	20.20*	13.70 ⁽¹⁾	17.99*	Valid up to January 11, 2027	8.55% ⁽¹⁾	8.55%*	Working capital facilities	-
5.	Citibank N.A. ⁽¹⁾	Transhealth Private Limited	April 3, 2025, read with the letter dated January 5, 2026 ³	N.A. ⁽²⁾	Cash credit	150.00 ⁽¹⁾	150.00*	127.56 ⁽¹⁾	134.11*	12 months from date of sanction letter	9.17% ⁽¹⁾	8.66%*	Working capital facilities and capital expenditure	Up to 2% per annum on the prepaid amount in case of loan prepayment (for the period computed as difference between the date of prepayment to the maturity date or next reset date whichever is earlier). However, in respect of Facilities with floating rate interest, no such charges will be payable if a prepayment of such Facility is made on an

Sr. No.	Name of the lender	Name of the borrower	Date of sanction letter / facility agreement	Loan disbursement dates(s)	Nature of borrowing	Amount sanctioned/ availed as on June 30, 2026 (₹ in million)	Amount sanctioned/ availed as on August 31, 2026 (₹ in million)*	Amount outstanding as on June 30, 2026 (₹ in million)	Amount outstanding as on August 31, 2026 (₹ in million)*	Tenor/ Repayment schedule	Interest rate as at June 30, 2026 (in %)	Interest rate as at August 31, 2026 (in %)*	Purpose for which the loan was availed ⁽¹⁾ and original purpose of the loan (in case subsequent loans are for refinancing / reimbursement / takeover of existing loans, etc.	Prepayment clause (if any)
														Interest Reset Date.
6.	Citi Bank N.A. ⁽¹⁾	Transhealth Private Limited	April 3, 2025, read with the letter dated January 5, 2026	January 15, 2024, February 26, 2024, June 18, 2024	Term Loan	93.40 ⁽¹⁾	93.40*	55.41 ⁽¹⁾	52.88*	Repayable on different monthly tenors	7.35%-8.61% ⁽¹⁾	3.65%-8.61%*	Working capital facilities and capital expenditure (acquisition of machine) ^{^^} Original purpose: working capital	Up to 2% per annum on the prepaid amount in case of loan prepayment (for the period computed as difference between the date of prepayment to the maturity date or next reset date whichever is earlier). However, in respect of Facilities with floating rate interest, no such charges will be payable if a prepayment of such Facility is made on an Interest Reset Date.
Total						1,463.60	1,463.60	1,152.15	1,124.49					

* Details as at August 31, 2026 are as certified by J.C. Bhalla & Co., Chartered Accountants (FRN: 001111N), by way of their certificate dated [●] (UDIN:[●]). Totals include amounts certified by Walker Chandiok & Co LLP and J.C. Bhalla & Co., as indicated against each line item.

** This facility has been renewed.

^ This facility has been renewed.

^{^^}The sanction letter refers the purpose of the loan as both working capital and capital expenditure. However, for assessment purposes, the entire loan has been treated as having been utilized solely for capital expenditure.

⁵ This facility has been renewed.

⁽¹⁾ In accordance with Clause 9(A)(2)(b) of Part A of Schedule VI of the SEBI ICDR Regulations which requires a certificate from the statutory auditor certifying the utilization of loan for the purpose availed, our Company has obtained the requisite report dated [●] (UDIN:[●]) from Walker Chandiok & Co LLP (FRN: 001076N/N500013), our statutory auditors, in respect of details as at June 30, 2026 of loans availed by Translumina Therapeutics Private Limited and Transhealth Private Limited, as marked (1) above.

⁽²⁾ Since these are working capital facilities, please note that there are no specific disbursal dates available for such facilities .

Utilisation of loans by our Step-Down Subsidiaries, namely, CPC Diagnostics Private Limited, Chemopharm Sdn. Bhd. and Research Instruments Pte. Ltd.

Sr. No.	Name of the lender	Name of the borrower	Date of sanction letter / facility agreement	Loan disbursement date(s)	Nature of borrowing	Amount sanctioned/ availed as on June 30, 2026 (₹ in million)	Amount sanctioned/ availed as on August 31, 2026 (₹ in million)*	Amount outstanding as on June 30, 2026 (₹ in million)	Amount outstanding as on August 31, 2026 (₹ in million)*	Tenor/ Repayment schedule	Interest rate as at June 30, 2026 (in %)	Interest rate as at August 31, 2026 (in %)*	Purpose for which the loan was availed(1) and original purpose of the loan (in case subsequent loans are for refinancing/ reimbursement /takeover of existing loans, etc	Prepayment clause (if any)
1.	Citi Bank N.A. ⁽¹⁾	CPC Diagnostics Private Limited	June 12, 2026	N.A. ⁽³⁾	Working Capital facilities a. Cash Credit b. Working capital demand Loan c. Non fund based - Bank Guarantee, Usance of Letter of credit, Buyers credit, Sight letter of credit	Sanction limits: ⁽¹⁾ Overall Sanction limit- ₹ 493.50 million includes: Working Capital - ₹ 475.00 Million i) Cash credit and working capital demand loan - ₹475.00million ii) Non- fund based limit (sub-limit) - ₹150.00million	Sanction limits: ⁽²⁾ Overall Sanction limit- ₹ 493.50 million includes: Working Capital - ₹ 475.00 Million i) Cash credit and working capital demand loan - ₹475.00million ii) Non- fund based limit (sub-limit) - ₹150.00million	306.61 ⁽¹⁾	384.42 ⁽²⁾	Cash credit: 12 months from date of utilisation Working capital loans: 6 months from the date of utilisation Non-fund based: Maximum tenor of seven years from the date of utilisation	i) Average interest rate for cash credit is 9.00 % p.a. ⁽¹⁾ ii) Average interest rate for trade pay is 6.75 % p.a. ⁽¹⁾ Average interest rate is 6.90% p.a	i) Average interest rate is 9.00 % p.a. ⁽²⁾ ii) Average interest rate is 6.71 % p.a. ⁽²⁾ Average interest rate is 6.90% p.a	i)Financing working capital requirements ii)Issuing bank guarantee to customers Original purpose: Financing working capital requirements	Up to 2% per annum on the prepaid amount in case of loan prepayment (for the period computed as difference between the date of prepayment to the maturity date or next reset date whichever is earlier). However, in respect of Facilities with floating rate interest, no such charges will be payable if a prepayment of such Facility is made on an Interest Reset Date
2.	Citi Bank N.A. ⁽¹⁾	CPC Diagnostics Private Limited	June 12, 2026	April 13, 2022	Term Loan	18.50 ⁽¹⁾	18.50 ⁽²⁾	18.00 ⁽¹⁾	13.50 ⁽²⁾	5 years with 20 equal quarterly instalments	9.07% ⁽¹⁾	9.09% ⁽²⁾	Reimbursement of capital expenditure incurred in Fiscal 2021 and Fiscal 2022 which was availed for purchasing instruments placed at laboratories and hospitals	Prepayment penalty at the rate of 2% of principal outstanding, at the discretion of Citibank N.A.

Sr. No.	Name of the lender	Name of the borrower	Date of sanction letter / facility agreement	Loan disbursement date(s)	Nature of borrowing	Amount sanctioned/ availed as on June 30, 2026 (₹ in million)	Amount sanctioned/ availed as on August 31, 2026 (₹ in million)*	Amount outstanding as on June 30, 2026 (₹ in million)	Amount outstanding as on August 31, 2026 (₹ in million)*	Tenor/ Repayment schedule	Interest rate as at June 30, 2026 (in %)	Interest rate as at August 31, 2026 (in %)*	Purpose for which the loan was availed(1) and original purpose of the loan (in case subsequent loans are for refinancing/ reimbursement /takeover of existing loans, etc	Prepayment clause (if any)
3.	HSBC Bank ⁽¹⁾	CPC Diagnostics Private Limited	March 6, 2025, read with letter dated February 23, 2026	N.A. ⁽³⁾	Cash credit	Combined Limit: ⁽¹⁾ ₹200.00million Working Capital Loan: ⁽¹⁾ ₹200.00(120 days + 1-day cooling)	Combined Limit: ⁽²⁾ ₹200.00 million Working Capital Loan: ⁽²⁾ ₹200.00(120 days + 1-day cooling) TradePay (Import): ⁽²⁾ ₹200.00 million or FCY equivalent (120 days)	63.92 ⁽¹⁾	31.01 ⁽²⁾	Working Capital Loan:(120 days + 1-day cooling) Overdraft: On Demand Others: 120 days Further, next renewal of the facility is due on November 30,2026	Average interest rate for cash credit is 7.39 % p.a. ⁽¹⁾ Average interest rate for trade pay is 6.85% p.a. ⁽¹⁾	Average interest rate for cash credit is 7.32 % p.a. ⁽²⁾ Average interest rate for trade pay is 6.85% p.a. ⁽²⁾	Financing working capital requirements.	Any prepayment will be subject to HSBC Bank's discretion.
				N.A. ⁽³⁾	Import/ Buyer Facility: TradePay (Import)			90.77 ⁽¹⁾	114.94 ⁽²⁾	Maximum 120 days from the date of utilisation.			To finance import/domestic payables of the borrower for the purposes of payment to suppliers for import of instruments and reagents	
4.	HSBC Bank ⁽¹⁾	Chemopharm Sdn. Bhd.	October 28, 2024	November 11,, 2024	Term Loan (US\$)	1,981.13 ⁽¹⁾	2,000.00 ⁽²⁾	1,827.36 ⁽¹⁾	1,943.82 ⁽²⁾	Repayment at different intervals from date of utilisation, i.e., 12, 18, 24, 30, 36, 42 or 48 months with different applicable interest rates. However, the maximum tenor available shall not exceed 60 months.	Margin + Reference rate ⁽¹⁾ As per sanction letter, Margin- 2.20% p.a Reference rate - the applicable Primary Term Rate for the applicable currency of a Loan as of the quotation Time for a period equal in length to the Interest Period of that Loan.	Margin + Reference rate ⁽²⁾ As per sanction letter, Margin- 2.20% p.a Reference rate - the applicable Primary Term Rate for the applicable currency of a Loan as of the quotation Time for a period equal in length to the Interest Period of that Loan.	A. Financing the direct repayment or prepayment of the Existing Financial Indebtedness by the Borrower and/or the direct repayment or prepayment by the Borrower of an intercompany loan between the Borrower and Chemoinformatics Sdn Bhd, the proceeds of which are used contemporaneously by Chemoinformatics Sdn Bhd for the repayment or prepayment of the Existing Financial Indebtedness;+ B. Financing the payment by the Group of deferred consideration related to acquisition of Thai Material Entity 1;+ and C.The payment of fees, costs	Illegality If, at any time, it is or will become unlawful in any applicable jurisdiction for a Lender to perform any of its obligations as contemplated by this Agreement or to fund or maintain its participation in any Loan or it is or will become unlawful for any Affiliate of a Lender for that Lender to

Sr. No.	Name of the lender	Name of the borrower	Date of sanction letter / facility agreement	Loan disbursement date(s)	Nature of borrowing	Amount sanctioned/ availed as on June 30, 2026 (₹ in million)	Amount sanctioned/ availed as on August 31, 2026 (₹ in million)*	Amount outstanding as on June 30, 2026 (₹ in million)	Amount outstanding as on August 31, 2026 (₹ in million)*	Tenor/ Repayment schedule	Interest rate as at June 30, 2026 (in %)	Interest rate as at August 31, 2026 (in %)*	Purpose for which the loan was availed(1) and original purpose of the loan (in case subsequent loans are for refinancing/ reimbursement /takeover of existing loans, etc	Prepayment clause (if any)
5.	HSBC Bank ⁽¹⁾	Chemopharm Sdn. Bhd.	October 28, 2024	November 11, 2024	Term Loan (MYR)	2,897.41 ⁽¹⁾	2,963.12 ⁽²⁾	2,730.02 ⁽¹⁾	2,814.96 ⁽²⁾		Margin + Reference rate ⁽¹⁾ As per sanction letter, Margin- 2.20% p.a Reference rate - the applicable Primary Term Rate for the applicable currency of a Loan as of the quotation Time for a period equal in length to the Interest Period of that Loan.	Margin + Reference rate ⁽²⁾ As per sanction letter, Margin- 2.20% p.a Reference rate - the applicable Primary Term Rate for the applicable currency of a Loan as of the quotation Time for a period equal in length to the Interest Period of that Loan.	A. Financing the direct repayment or prepayment of the Existing Financial Indebtedness by the Borrower and/or the direct repayment or prepayment by the Borrower of an intercompany loan between the Borrower and Chemoinformatics Sdn Bhd, the proceeds of which are used contemporaneously by Chemoinformatics Sdn Bhd for the repayment or prepayment of the Existing Financial Indebtedness; B. Financing the payment by the Group of deferred consideration related to acquisition of Thai Material Entity I; and C.The payment of fees, costs and expenses incurred and payable by the Borrower under the Finance Documents	do so: (a) that Lender shall promptly notify the Agent upon becoming aware of that event; (b) upon the Agent notifying the Borrower, each Available Commitment of that Lender will be immediately cancelled; and (c) to the extent that the Lender's participation has not been transferred pursuant to Clause 35.6 (Replacement of Lender), the Borrower shall repay that Lender's participation in the Utilizations made to the Borrower on the earliest of the following dates: (i) the last day of the Interest Period for each Loan occurring immediately after the Agent has notified the Borrower; and (ii) the date specified by that Lender in the notice

Sr. No.	Name of the lender	Name of the borrower	Date of sanction letter / facility agreement	Loan disbursement date(s)	Nature of borrowing	Amount sanctioned/ availed as on June 30, 2026 (₹ in million)	Amount sanctioned/ availed as on August 31, 2026 (₹ in million)*	Amount outstanding as on June 30, 2026 (₹ in million)	Amount outstanding as on August 31, 2026 (₹ in million)*	Tenor/ Repayment schedule	Interest rate as at June 30, 2026 (in %)	Interest rate as at August 31, 2026 (in %)*	Purpose for which the loan was availed(1) and original purpose of the loan (in case subsequent loans are for refinancing/ reimbursement /takeover of existing loans, etc	Prepayment clause (if any)
														delivered to the Borrower (being no earlier than the last day of any applicable grace period permitted by law), and that Lender's corresponding Commitment(s) shall be cancelled in the amount of the participation repaid. Mandatory prepayment - Flotation or Change of Control (a) Upon the occurrence of: (i) a Change of Control; (ii) a Flotation that is not an Approved Flotation; (iii) the sale of all or substantially all of the assets of the Group whether in a single transaction or a series of related transactions, the Obligors' Agent shall promptly notify the Agent upon becoming aware of that event and: (A) no Lender shall not be obliged to fund

Sr. No.	Name of the lender	Name of the borrower	Date of sanction letter / facility agreement	Loan disbursement date(s)	Nature of borrowing	Amount sanctioned/ availed as on June 30, 2026 (₹ in million)	Amount sanctioned/ availed as on August 31, 2026 (₹ in million)*	Amount outstanding as on June 30, 2026 (₹ in million)	Amount outstanding as on August 31, 2026 (₹ in million)*	Tenor/ Repayment schedule	Interest rate as at June 30, 2026 (in %)	Interest rate as at August 31, 2026 (in %)*	Purpose for which the loan was availed(1) and original purpose of the loan (in case subsequent loans are for refinancing/ reimbursement /takeover of existing loans, etc	Prepayment clause (if any)
														a Utilisation; and (B) the Total Commitments will be cancelled and all outstanding Loans, together with accrued interest and all other amounts accrued under the Finance Documents will become immediately due and payable by the Borrower.
6.	Malayan Banking Berhad ⁽¹⁾	Chemopharm Sdn. Bhd.	December 13, 2023, read with letter dated November 27, 2025	N.A. ⁽³⁾	Multiple bank facility	254.97 ⁽¹⁾	215.31 ⁽²⁾	153.12 ⁽¹⁾	162.71 ⁽²⁾	Repayable on demand	FEC: Forex Rate ⁽¹⁾ LC: Commission at 0.10% per month (Minimum RM75.00) TR: Base Lending Rate (BLR) + 1.25% per annum BA: 1.25% acceptance commission Invoice Financing (IF) for Goods: Cost of Fund (COF) + 1.25% per annum, based on selected currencies. Repricing not allowed Invoice Financing (IF) for Services: COF + 1.25% per annum, based on selected currencies. Repricing not allowed BG: Commission at 0.10% per month (Minimum	FEC: Forex Rate ⁽²⁾ LC: Commission at 0.10% per month (Minimum RM75.00) TR: Base Lending Rate (BLR) + 1.25% per annum BA: 1.25% acceptance commission Invoice Financing (IF) for Goods: Cost of Fund (COF) + 1.25% per annum, based on selected currencies. Repricing not allowed Invoice Financing (IF) for Services: COF + 1.25% per annum, based on selected currencies. Repricing not allowed BG: Commission	Foreign Exchange contract limit (FECL): To hedge against foreign exchange fluctuation for foreign purchases/sales made during normal trade transactions. Letter of Credit (LC) - Sight/Usance: 120 days Trust Receipt (TR) Tenor: 120 days Banker's Acceptance (BA)-For Purchase/Imports-Tenor: 120 days Invoice Financing (IF) for Goods-For Purchase/Imports-Tenor: 120 days Invoice Financing (IF) for Services -Tenor: 120 days Bank Guarantee (BG) - Financial/Non-Financial Standby Letter of Credit (SBLC) Onshore Foreign Currency Loan (OFCL)-For Imports-Tenor: 120 days Original purpose: working capital	One (1) month's prior written notice or by paying one (1) month's interest in lieu of notice.


Sr. No.	Name of the lender	Name of the borrower	Date of sanction letter / facility agreement	Loan disbursement date(s)	Nature of borrowing	Amount sanctioned/availed as on June 30, 2026 (₹ in million)	Amount sanctioned/availed as on August 31, 2026 (₹ in million)*	Amount outstanding as on June 30, 2026 (₹ in million)	Amount outstanding as on August 31, 2026 (₹ in million)*	Tenor/Repayment schedule	Interest rate as at June 30, 2026 (in %)	Interest rate as at August 31, 2026 (in %)*	Purpose for which the loan was availed(1) and original purpose of the loan (in case subsequent loans are for refinancing/ reimbursement /takeover of existing loans, etc	Prepayment clause (if any)
											RM100.00) SBLC: Commission at 0.10% per month (Minimum RM100.00) OFCL: COF + 1.25% per annum, based on selected foreign currencies	at 0.10% per month (Minimum RM100.00) SBLC: Commission at 0.10% per month (Minimum RM100.00) OFCL: COF + 1.25% per annum, based on selected foreign currencies		
7.	CIMB Bank ⁽¹⁾	Chemopharm Sdn Bhd	July 22, 2024	N.A. ⁽³⁾	Multiple bank facility	162.26 ⁽¹⁾	165.93 ⁽²⁾	123.27 ⁽¹⁾	161.45 ⁽²⁾	FELC/ BG/ OD: Repayable on demand BA/ DC/ TR: Upon maturity of the tenor and/or repayable on demand, whichever is earlier	OD-Bank Base rate +1.25% ⁽¹⁾ DC- 0.10%per month TR-Bank Base rate +1.25% BA-1% per annum BG-0.15% per month FECL-Prevailing Foreign exchange rate	OD-Bank Base rate +1.25% ⁽²⁾ DC- 0.10%per month TR-Bank Base rate +1.25% BA-1% per annum BG-0.15% per month FECL-Prevailing Foreign exchange rate	Foreign Exchange contract limit (FECL): To hedge against foreign exchange fluctuation for foreign purchases/sales made during normal trade transactions. Overdraft (OD): For working capital requirements. Bank guarantee (BG): For tender, performance and deposits to utilities/customs/immigrations. Banker Acceptance (BA): To finance purchases/imports of trade-related goods. Documentary credit (DC): To facilitate importation and purchase of goods. Trust receipt (TR): To finance goods under DC and Inwards Bills of Collection Original purpose: working capital	No prepayment of the Facilities may be available for redrawing or be reborrowed unless agreed upon by the Bank in writing
8.	Standard Chartered Bank ⁽¹⁾	Chemopharm Sdn Bhd	June 4, 2025**	N.A. ⁽³⁾	Multiple bank facility	324.51 ⁽¹⁾	331.87 ⁽²⁾	278.18 ⁽¹⁾	300.88 ⁽²⁾	Maximum tenure of 150 days from the date of utilisation.	1.20% p.a. over the cost of the funds ⁽¹⁾	1.20% p.a. over the cost of the funds ⁽²⁾	Letters of Credit ("LC") Secured/Unsecured-Drafts and/or documents payable at sight or usance Import Loan-Import Loans covering the release of goods imported by the Borrower under and in relation to Letters of Credit issued or import bills for collection handled by the Bank. Invoice financing-For	-

Sr. No.	Name of the lender	Name of the borrower	Date of sanction letter / facility agreement	Loan disbursement date(s)	Nature of borrowing	Amount sanctioned/ availed as on June 30, 2026 (₹ in million)	Amount sanctioned/ availed as on August 31, 2026 (₹ in million)*	Amount outstanding as on June 30, 2026 (₹ in million)	Amount outstanding as on August 31, 2026 (₹ in million)*	Tenor/ Repayment schedule	Interest rate as at June 30, 2026 (in %)	Interest rate as at August 31, 2026 (in %)*	Purpose for which the loan was availed(1) and original purpose of the loan (in case subsequent loans are for refinancing/ reimbursement /takeover of existing loans, etc	Prepayment clause (if any)
													financing goods purchased by the Borrower from its seller, as evidenced by the seller's invoice to the Borrower. Original purpose: Funding working capital requirements	
9.	HSBC Bank ⁽⁴⁾	Research Instruments Pte. Ltd.	November 5, 2024	N.A.	Trust Receipts	343.37	352.35	137.23	217.04	The Subsidiary Company has availed Loan against import with Trust Receipt at the rate of SOFR (Secured Overnight Financing Rate) Term Rate + Margin 2%, as conclusively determined by the bank from time to time*BRL + 2% p.a. over the bank's cost of funds, as conclusively determined by the bank from time to time	SOFR (Secured Overnight Financing Rate) Term Rate + Margin 2%, as conclusively determined by the bank from time to time	SOFR (Secured Overnight Financing Rate) Term Rate + Margin 2%, as conclusively determined by the bank from time to time	Working Capital Requirement	-
Total						6,675.65	6,740.58	5,728.48	6,144.73					

*The outstanding amount is more than the sanctioned amount due to fluctuations in exchange rates.

⁴Chemopharm Sdn. Bhd. ("Chemopharm") had availed a term loan (in USD) ("Main Loan 1") and term loan (in MYR) ("Main Loan 2") from HSBC Bank ("Lender") pursuant to sanction letters each dated October 28, 2024 (Main Loan 1 and Main Loan 2 collectively referred to as "Main Loans"), which we propose to repay/prepay (in full or in part) from the Net Proceeds. Prior to this, Chemoinformatics Sdn. Bhd. ("Chemoinformatics") had availed a loan from Standard Chartered Bank and Malayan Banking Berhad (collectively, "Original Lenders") pursuant to the facilities agreement dated June 7, 2022, read with the amended and restated agreement dated January 30, 2024 for an amount of MYR 65,000,000 ("Original Loan" and such amount, the "Original Loan Amount"). The purpose of the Original Loan was to facilitate the acquisition of Hausen Bernstein Company Limited by Chemopharm. To facilitate this, Chemoinformatics had lent the Original Loan Amount to Chemopharm through an inter-company loan ("Inter-Company Loan"), such that Chemopharm could acquire the shares of Hausen Bernstein Company Limited. Accordingly, Chemopharm utilised the Inter-Company Loan for the purposes of acquiring Hausen Bernstein Company Limited. Thereafter, Chemopharm availed the abovementioned Main Loans to, among others, refinance the Inter-Company Loan and repay Chemoinformatics, which was thereafter used by Chemoinformatics to repay the Original Loan Amount. As on August 31, 2026 the amount sanctioned under Main Loan 1 was ₹ 2,000.00 million and the amount sanctioned under Main Loan 2 was ₹ 2,963.12 million. Further, as on August 31, 2026, the amount outstanding under Main Loan 1 was ₹ 1,943.82 million and the amount outstanding under Main Loan 2 was ₹ 2,814.96 million. Set forth below is a pictorial diagram of the Main Loans vis-à-vis the Original Loan and the Inter-Company Loan:

Flow Chart of Net proceeds for Repayment of Loan



Note 1 - This flowchart represents the roadmap of the Loan taken by CPM from HSBC in October 2024 which is to be repaid via IPO proceeds of Integrus Medtech.

Note 2 - The Loan was utilised for the purposes of (i) direct repayment/prepayment of existing financial indebtedness of Chemopharm, (ii) financing the payment by the Group (i.e. Chemopharm and its subsidiaries) of deferred consideration related to the acquisition of Hausen Bernstein Company Limited, and (iii) payment of fees, costs and expenses incurred and payable by Chemopharm under the finance documents.

Note 3 - CPM : Chemopharm Sdn Bhd, Hausen : Hausen Bernstein Company Limited, CIM : Cheminformatics Sdn Bhd (Subsidiary of CPM).

Note 4- The loan amounts represent sanctioned amounts of the loan taken from HSBC Bank by Chemopharm Sdn Bhd as on August 31, 2025.

- (1) In accordance with Clause 9(A)(2)(b) of Part A of Schedule VI of the SEBI ICDR Regulations which requires a certificate from the statutory auditor certifying the utilization of loan for the purpose availed, our Company has obtained the requisite report dated [●] (UDIN:[●]) from Walker Chandio & Co LLP (FRN: 001076N/N500013), our statutory auditors, in respect of details as at June 30, 2026 of loans availed by CPC Diagnostics Private Limited and Chemopharm Sdn. Bhd., as marked (1) above.
- (2) In accordance with Clause 9(A)(2)(b) of Part A of Schedule VI of the SEBI ICDR Regulations which requires a certificate from the statutory auditor/independent chartered accountant certifying the utilization of loan as at August 31, 2026, as marked (2) above, have been certified by way of certificate dated [●] (UDIN:[●]) from J.C. Bhalla & Co, Chartered Accountants (FRN: 001111N).
- (3) Since these are working capital facilities, please note that there are no specific disbursement dates available for such facilities.
- (4) The details of loan availed by Research Instruments Pte. Ltd., as marked (4) above, including as at June 30, 2026 and utilisation thereof, have been certified by J.C. Bhalla & Co, Chartered Accountants (FRN: 001111N) by their certificate dated [●].

Note:

Sanctioned Amount relates to foreign currency loans that has been translated at closing exchange as on reporting date. The Outstanding balances as at June 30, 2026 of respective facility is taken as per books of accounts, while the balances as at August 31, 2026 is balances as per bank statements. Totals include amounts certified by Walker Chandio & Co LLP and J.C. Bhalla & Co., as indicated as (1), (2) or (4) against each line item.

The following table bifurcates between the purpose of the Identified Loans availed by our Wholly-Owned Subsidiaries and our Step-Down Subsidiaries, as applicable, i.e., whether the Identified Loans were availed for the purposes of capital expenditure or for purposes other than capital expenditure

I. Identified Loans availed for the purposes of capital expenditure

The following table set forth details of the Identified Loans availed for the purposes of capital expenditure by our Wholly-Owned Subsidiaries and our Step-Down Subsidiaries, as applicable, which are outstanding as on June 30, 2026 and August 31, 2026, which we may repay/ prepay, all or a portion of, from the Net Proceeds.

Sr. No.	Name of the lender	Name of the borrower	Date of sanction letter / facility agreement	Nature of borrowing	Amount outstanding as on June 30, 2026 (₹ in million)	Amount outstanding as on August 31, 2026 (₹ in million)*	Purpose for which the loan was availed ⁽¹⁾
Wholly-Owned Subsidiaries							
1.	Citi Bank N.A. ⁽¹⁾	Transhealth Private Limited	April 3, 2025, read with the letter dated January 5, 2026 ^s	Term Loan	55.41	52.88	Working capital facilities and capital expenditure (acquisition of machine)^
Step-Down Subsidiaries							
2.	Citi Bank N.A. ⁽¹⁾	CPC Diagnostics Private Limited	June 12, 2026	Term Loan	18.00	13.50	Reimbursement of capital expenditure incurred in Fiscal 2021 and Fiscal 2022 which was availed for purchasing instruments placed at laboratories and hospitals
3.	HSBC Bank ⁽¹⁾	Chemopharm Sdn. Bhd.	October 28, 2024	Term Loan	1,849.28	1,943.82	A. Financing the direct repayment or prepayment of the Existing Financial Indebtedness by the Borrower and/or the direct repayment or prepayment by the Borrower of an intercompany loan between the Borrower and Chemoinformatics Sdn. Bhd., the proceeds of which are used contemporaneously by Chemoinformatics Sdn. Bhd. for the repayment or prepayment of the Existing Financial Indebtedness;+ B. Financing the payment by the Group of deferred consideration related to acquisition of Thai Material Entity

Sr. No.	Name of the lender	Name of the borrower	Date of sanction letter / facility agreement	Nature of borrowing	Amount outstanding as on June 30, 2026 (₹ in million)	Amount outstanding as on August 31, 2026 (₹ in million)*	Purpose for which the loan was availed ⁽¹⁾
							1; ⁺ and C. The payment of fees, costs and expenses incurred and payable by the Borrower under the Finance Documents
4.	HSBC Bank ⁽¹⁾	Chemopharm Sdn. Bhd.	October 28, 2024	Term Loan	2,714.67	2,814.96	A. Financing the direct repayment or prepayment of the Existing Financial Indebtedness by the Borrower and/or the direct repayment or prepayment by the Borrower of an intercompany loan between the Borrower and Chemoinformatics Sdn. Bhd., the proceeds of which are used contemporaneously by Chemoinformatics Sdn. Bhd. for the repayment or prepayment of the Existing Financial Indebtedness; B. Financing the payment by the Group of deferred consideration related to acquisition of Thai Material Entity 1; and C. The payment of fees, costs and expenses incurred and payable by the Borrower under the Finance Documents
Total					4,637.36	4,825.16	

* As certified by J.C. Bhalla & Co., Chartered Accountants (FRN: 001111N), by way of their certificate dated [●] [●] (UDIN:[●]).

** This facility has been renewed.


% The outstanding amount is more than the sanctioned amount due to fluctuations in exchange rates.

^ The sanction letter refers the purpose of the loan as both working capital and capital expenditure. However, for assessment purposes, the entire loan has been treated as having been utilized solely for capital expenditure.

+ Chemopharm Sdn. Bhd. (“**Chemopharm**”) had availed a term loan (in USD) (“**Main Loan 1**”) and term loan (in MYR) (“**Main Loan 2**”) from HSBC Bank (“**Lender**”) pursuant to sanction letters each dated October 28, 2024 (Main Loan 1 and Main Loan 2 collectively referred to as “**Main Loans**”), which we propose to repay/prepay (in full or in part) from the Net Proceeds. Prior to this, Chemoinformatics Sdn. Bhd. (“**Chemoinformatics**”) had availed a loan from Standard Chartered Bank and Malayan Banking Berhad (collectively, “**Original Lenders**”) pursuant to the facilities agreement dated June 7, 2022, read with the amended and restated agreement dated January 30, 2024 for an amount of MYR 65,000,000 (“**Original Loan**” and such amount, the “**Original Loan Amount**”). The purpose of the Original Loan was to facilitate the acquisition of Hausen Bernstein Company Limited by Chemopharm. To facilitate this, Chemoinformatics had lent the Original Loan Amount to Chemopharm through an inter-company loan (“**Inter-Company Loan**”), such that Chemopharm could acquire the shares of Hausen Bernstein Company Limited. Accordingly, Chemopharm utilised the Inter-Company Loan for the purposes of acquiring Hausen Bernstein Company Limited. Thereafter, Chemopharm availed the abovementioned Main Loans to, among others, refinance the Inter-Company Loan and repay Chemoinformatics, which was thereafter used by Chemoinformatics to repay the Original Loan Amount. As on August 31, 2026 the amount sanctioned under Main Loan 1 was ₹ 2,000.00 million and the amount sanctioned under Main Loan 2 was ₹

2,963.12 million. Further, as on August 31, 2026, the amount outstanding under Main Loan 1 was ₹ 1,943.82 million and the amount outstanding under Main Loan 2 was ₹ 2,814.96 million. Set forth below is a pictorial diagram of the Main Loans vis-à-vis the Original Loan and the Inter-Company Loan:

Flow Chart of Net proceeds for Repayment of Loan



Note 1 - This flowchart represents the roadmap of the Loan taken by CPM from HSBC in October 2024 which is to be repaid via IPO proceeds of Integris Medtech.

Note 2 - The Loan was utilised for the purposes of (i) direct repayment/prepayment of existing financial indebtedness of Chemopharm, (ii) financing the payment by the Group (i.e. Chemopharm and its subsidiaries) of deferred consideration related to the acquisition of Hausen Bernstein Company Limited, and (iii) payment of fees, costs and expenses incurred and payable by Chemopharm under the finance documents.

Note 3 - CPM : Chemopharm Sdn Bhd, Hausen : Hausen Bernstein Company Limited, CIM : Cheminformatics Sdn Bhd (Subsidiary of CPM).

Note 4 - The loan amounts represent sanctioned amounts of the loan taken from HSBC Bank by Chemopharm Sdn Bhd as on August 31, 2025.

⁽¹⁾ In accordance with Clause 9(A)(2)(b) of Part A of Schedule VI of the SEBI ICDR Regulations which requires a certificate from the statutory auditor certifying the utilization of loan for the purpose availed, our Company has obtained the requisite report dated [●] (UDIN:[●]) from Walker Chandiok & Co LLP (FRN: 001076N/N500013), our statutory auditors.

II. Identified Loans availed for purposes other than capital expenditure

The following table set forth details of the Identified Loans availed for purposes other than capital expenditure by our Wholly-Owned Subsidiaries and our Step-Down Subsidiaries, as applicable, which are outstanding as on June 30, 2026 and August 31, 2026, as applicable, which we may repay/ prepay, all or a portion of, from the Net Proceeds.

Sr. No.	Name of the lender	Name of the borrower	Date of sanction letter / facility agreement	Nature of borrowing	Amount outstanding as on June 30, 2026 (₹ in million)	Amount outstanding as on August 31, 2026 (₹ in million)	Purpose for which the loan was availed ⁽¹⁾
Wholly-Owned Subsidiaries							
1.	Citibank, N.A.	Translumina Therapeutics Private Limited	January 2, 2026	Cash credit	491.90	431.22	Financing its Working capital requirements
2.	HDFC Bank	Translumina Therapeutics Private Limited	March 17, 2026**	Cash Credit	141.59	116.87	Business purpose for purchasing raw materials, making payments to vendors and service payments
				Buyer Credit	260.63	288.88	
3.	ICICI Bank	Translumina Therapeutics Private Limited	January 9, 2026	Cash Credit	61.36	82.54	Working capital facilities
4.	ICICI Bank	Transhealth Private Limited	January 13, 2026	Cash Credit	13.70	17.99	Working capital facilities

Sr. No.	Name of the lender	Name of the borrower	Date of sanction letter / facility agreement	Nature of borrowing	Amount outstanding as on June 30, 2026 (₹ in million)	Amount outstanding as on August 31, 2026 (₹ in million)	Purpose for which the loan was availed ⁽¹⁾
5.	Citibank N.A.	Transhealth Private Limited	January 5, 2026	Cash credit	127.56	134.11 -	Working capital facilities
Step-Down Subsidiaries							
1.	Citi Bank N.A.	CPC Diagnostics Private Limited	June 12, 2026**	Working Capital facilities a. Cash Credit b. Working capital demand Loan c. Non fund based - Bank Guarantee, Usance of Letter of credit, Buyers credit, Sight letter of credit d. Term Loan	306.61	384.42	i) Financing working capital requirements ii) Issuing bank guarantee to customers
2.	HSBC Bank	CPC Diagnostics Private Limited	February 23, 2026	Cash credit	63.92	31.01	Financing working capital requirements.
				Import/ Buyer Facility: TradePay (Import)	90.77	114.94	To finance import/domestic payables of the borrower for the purposes of payment to suppliers for import of instruments and reagents
3.	Malayan Banking Berhad	Chemopharm Sdn. Bhd.	November 27, 2025	Multiple bank facility	153.12	162.71	Foreign Exchange contract limit (FECL): To hedge against foreign exchange fluctuation for foreign purchases/sales made during normal trade transactions. Letter of Credit (LC) - Sight/Usance: 120 days Trust Receipt (TR) Tenor: 120 days Banker's Acceptance (BA)-For Purchase/Imports-Tenor: 120 days Invoice Financing (IF) for Goods-For Purchase/Imports-Tenor: 120 days Invoice Financing (IF) for Services -Tenor: 120 days Bank Guarantee (BG) - Financial/Non-Financial Standby Letter of Credit (SBLC) Onshore Foreign Currency

Sr. No.	Name of the lender	Name of the borrower	Date of sanction letter / facility agreement	Nature of borrowing	Amount outstanding as on June 30, 2026 (₹ in million)	Amount outstanding as on August 31, 2026 (₹ in million)	Purpose for which the loan was availed ⁽¹⁾
							Loan (OFCL)-For Imports-Tenor: 120 days
4.	CIMB Bank	Chemopharm Sdn. Bhd.	July 22, 2024	Multiple bank facility	123.27	161.45	Foreign Exchange contract limit (FECL): To hedge against foreign exchange fluctuation for foreign purchases/sales made during normal trade transactions. Overdraft (OD): For working capital requirements. Bank guarantee (BG): For tender, performance and deposits to utilities/customs/immigrations. Banker Acceptance (BA): To finance purchases/imports of trade-related goods. Documentary credit (DC): To facilitate importation and purchase of goods. Trust receipt (TR): To finance goods under DC and Inwards Bills of Collection
5.	Standard Chartered Bank	Chemopharm Sdn. Bhd.	June 4, 2025**	Multiple bank facility	278.18	300.88	Letters of Credit ("LC") Secured/Unsecured-Drafts and/or documents payable at sight or usance Import Loan-Import Loans covering the release of goods imported by the Borrower under and in relation to Letters of Credit issued or import bills for collection handled by the Bank. Invoice financing-For financing goods purchased by the Borrower from its seller, as evidenced by the seller's invoice to the Borrower.
11.	HSBC Bank	Research Instruments Pte. Ltd.	November 5, 2024	Trust Receipts	137.23	217.04	Working Capital Requirement
Total					2,249.84	2,444.06	

**This facility has been renewed.

For further details on the abovementioned borrowings, see “*Financial Indebtedness –Principal terms of subsisting borrowings availed by our Company and our Subsidiaries*” on page [●].

Details of our Wholly-Owned Subsidiaries and Step-Down Subsidiaries

Set forth below are (i) certain key financial information, and (ii) the shareholding pattern of our Wholly-Owned Subsidiaries, namely, Translumina Therapeutics and Transhealth and our Step-Down Subsidiaries, namely, CPC Diagnostics Private Limited, Chemopharm Sdn. Bhd.. and Research Instruments Pte. Ltd.

For further details, also see “*History and Certain Corporate Matters – Our Subsidiaries*” on page [●].

Translumina Therapeutics

Key financial information

Set forth below are key financial information of Translumina Therapeutics for the six months period ended June 30, 2026 and the Financial Years ended March 31, 2026, March 31, 2025 and March 31, 2024:

(in ₹ million, unless otherwise stated)

Particulars	As at and for the three months period ended June 30, 2026	As at and for Financial Year ended March 31, 2026	As at and for Financial Year ended March 31, 2025	As at and for Financial Year ended March 31, 2024
Equity share capital	0.10	0.10	0.10	Nil
Preference share capital	-	Nil	Nil	Nil
Revenue from operations	1,201.54	4,577.53	4,454.80	3,901.43
Other income	39.75	148.89	193.32	80.04
Total income	1,241.29	4,726.43	4,648.12	3,981.47
Restated profit for the period/year	(16.33)	165.84	89.76	326.07
Revenue from operations as a percentage of consolidated revenue (in %)	16.36	17.75	23.42%	25.12%
Reserves (excluding revaluation reserves)	431.80	443.41	286.88	342.74
Earnings per share (Basic) (face value of ₹ 1)	(146.43)	1,675.27	(2,852.07)	NA
Earnings per share (Diluted) (face value of ₹ 1)	(146.43)	1,675.27	(2,852.07)	NA
Total borrowings	2,520.99	2,216.68	2,518.50	859.79
Net worth	431.90	443.41	286.98	1,990.33
Net asset value	4,276.10	4,390.09	2,841.27	Nil

Note:

- (1) Revenue from operations also corresponds to the total sales generated during the relevant financial period/year
- (2) Restated profit for the period/year also corresponds to the profit after tax for the relevant financial period/year

Shareholding pattern

As on the date of this Draft Red Herring Prospectus, the shareholding pattern of Translumina Therapeutics is as follows:

Name of the shareholder	Number of equity shares of ₹ 1 each	Percentage of shareholding (%)
Our Company	100,001	99.01
Avnish Mehra*	999	0.99
Vishal Sharma*	1	Negligible
Punita Sharma*	1	Negligible
Vishal Omprakash Goenka*	1	Negligible
Total	101,003	100.00

* As a nominee of our Company.

Transhealth Private Limited

Key financial information

Set forth below are key financial information of Transhealth Private Limited for the three months period ended June 30, 2026 and the Financial Years ended March 31, 2026, March 31, 2025 and March 31, 2024:

(in ₹ million, unless otherwise stated)

Particulars	As at and for the three months period ended June 30, 2026	As at and for Financial Year ended March 31, 2026	As at and for Financial Year ended March 31, 2025	As at and for Financial Year ended March 31, 2024
Equity share capital	30.00	30.00	30.00	30.00
Preference share capital	Nil	Nil	Nil	Nil
Revenue from operations	134.44	610.12	793.89	376.40
Other income	3.11	16.46	27.70	12.76

Particulars	As at and for the three months period ended June 30, 2026	As at and for Financial Year ended March 31, 2026	As at and for Financial Year ended March 31, 2025	As at and for Financial Year ended March 31, 2024
Total income	137.55	626.58	821.59	389.16
Restated profit for the period/year	14.55	17.81	74.30	57.18
Revenue from operations as a percentage of consolidated revenue (in %)	1.83	2.37	4.17	2.42
Reserves (excluding revaluation reserves)	213.57	198.42	180.77	105.48
Earnings per share (Basic) (face value of ₹ 10)	4.95	5.86	24.77	18.93
Earnings per share (Diluted) (face value of ₹ 10)	4.95	5.86	24.77	18.93
Total borrowings	799.00	784.27	693.32	748.78
Net worth	243.57	228.42	210.77	135.48
Net asset value	81.19	76.14	70.26	45.16

Note:

- (1) Revenue from operations also corresponds to the total sales generated during the relevant financial period/year
(2) Restated profit for the period/year also corresponds to the profit after tax for the relevant financial period/year

As on the date of this Draft Red Herring Prospectus, the shareholding pattern of Transhealth Private Limited is as follows:

Name of the shareholder	Number of equity shares of ₹ 10 each	Percentage of shareholding (%)
Our Company	2,999,999	100.00
Vishal Sharma*	1	Negligible
Total	3,000,000	100.00

*As nominee of our Company

CPC Diagnostics Private Limited

Key financial information

Set forth below are key financial information of CPC Diagnostics Private Limited for the three months period ended June 30, 2026 and the Financial Years ended March 31, 2026, March 31, 2025 and March 31, 2024:

(in ₹ million, unless otherwise stated)

Particulars	As at and for the three months period ended June 30, 2026	As at and for Financial Year ended March 31, 2026	As at and for Financial Year ended March 31, 2025	As at and for Financial Year ended March 31, 2024
Equity share capital	61.41	61.41	61.04	61.04
Preference share capital	-	-	-	-
Revenue from operations	876.05	3,227.31	2,743.60	2,455.13
Other income	7.29	12.88	10.68	11.60
Total income	883.34	3,240.19	2,754.28	2,466.73
Restated profit for the period/year	59.98	126.34	143.61	95.11
Revenue from operations as a percentage of consolidated revenue (in %)	11.93	12.52	14.42	15.81
Reserves (excluding revaluation reserves)	1,245.25	1,185.09	1,057.30	951.22
Earnings per share (Basic) (face value of ₹ 100)	97.67	206.30	235.27	155.82
Earnings per share (Diluted) (face value of ₹ 100)	97.67	205.74	233.86	155.10
Total borrowings	479.68	539.14	319.87	196.41
Net worth	1,306.66	1,246.50	1,118.34	1,012.26
Net asset value	2,127.87	2,035.42	1,832.19	1,658.39

Note:

- (1) Revenue from operations also corresponds to the total sales generated during the relevant financial period/year
(2) Restated profit for the period/year also corresponds to the profit after tax for the relevant financial period/year

As on the date of this Draft Red Herring Prospectus, the shareholding pattern of CPC Diagnostics Private Limited, India is as follows:

Name of shareholder	Number of equity shares of ₹ 100 each	Percentage of shareholding (%)
Everlife Holdings Pte. Ltd.	396,750	64.61
Our Company	65,196	10.62
Malini Kailasnath	42,969	7.00
Bhuvana Panchanath	39,412	6.42
Radhakrishnan Kailasnath	30,228	4.92
Radhakrishnan Panchanath	25,241	4.11
Pramod Kabra	4,028	0.66
Rohan Panchanath	2,100	0.34
K Ashwin Narayan	1,050	0.17
K Vivek Radhakrishnan	1,050	0.17
Gopinathan V.	910	0.15
Venkatasubramaniam Ramesh	910	0.15
Sivaramakrishnan C	840	0.14
P Naresh Kumar	532	0.09
K Hemadri	441	0.07
Alex Vizhalil Paul	406	0.07
Seshadhri S	350	0.06
U Srin	343	0.06
Gorle Ravi	255	0.04
Govindan S V	217	0.04
D Latha	210	0.03
D Sathish Kumar	168	0.03
T Anandh	140	0.02
Abhay Kumar	105	0.02
Sangeetha R	84	0.01
Raji Subbarayan	71	0.01
Mohideen Khan U	35	0.01
Srimika Pranav Khismatrao	28	Negligible
Total	614,069	100.00

Note: Pursuant to the share purchase agreement dated February 24, 2026, the remaining 152,123 equity shares held by shareholders other than Everlife and the Company, will be transferred by September 30, 2026 or March 31, 2027 or any mutually decided date

Chemopharm Sdn. Bhd.

Key financial information

Set forth below are key financial information of Chemopharm Sdn. Bhd. for the three months period ended June 30, 2026 and the Financial Years ended March 31, 2026, March 31, 2025 and March 31, 2024:

Particulars	(in ₹ million, unless otherwise stated)			
	As at and for the three months period ended June 30, 2026 ⁽¹⁾	As at and for Financial Year ended March 31, 2026 ⁽²⁾	As at and for Financial Year ended March 31, 2025 ⁽²⁾	As at and for Financial Year ended March 31, 2024 ⁽³⁾
Equity share capital	592.90	595.65	394.80	359.95
Preference share capital	-	-	-	-
Revenue from operations	1,290.90	4,268.06	2,647.93	2,259.58
Other income	175.36	1,212.24	547.56	504.18
Total income	1,466.26	5,480.30	3,195.49	2,763.76
Restated profit for the period/year	259.86	1,245.63	431.28	227.09
Revenue from operations as a percentage of consolidated revenue (in %)	17.58	16.55	13.92	14.55
Reserves (excluding revaluation reserves)	4,057.75	3,820.32	2,030.09	1,446.16

Particulars	As at and for the three months period ended June 30, 2026 ⁽¹⁾	As at and for Financial Year ended March 31, 2026 ⁽²⁾	As at and for Financial Year ended March 31, 2025 ⁽²⁾	As at and for Financial Year ended March 31, 2024 ⁽³⁾
Earnings per share (Basic)	43.83	210.03	75.87	39.94
Earnings per share (Diluted)	43.83	210.03	72.67	38.33
Total borrowings	5,743.99	5,888.84	4,823.18	4,305.43
Net worth	4,650.65	4,415.97	2,424.90	1,806.12
Net asset value	784.38	744.80	426.87	317.94

(1) Calculated basis the exchange rate of MYR 1 = ₹ 23.23, as of June 30, 2026 and an average exchange rate of MYR 1 = ₹ 23.67 for the three months period ended June 30, 2026

(2) Calculated basis the exchange rate of MYR 1 = ₹ 23.34, as of March 31, 2026 and an average exchange rate of MYR 1 = ₹ 21.26 for the Financial Year ended March 31, 2026

(3) Calculated basis the exchange rate of MYR 1 = ₹ 19.32 as of March 31, 2025 and an average exchange rate of MYR 1 = ₹ 18.78 for the Financial Year ended March 31, 2025

(4) Calculated basis the exchange rate of MYR 1 = ₹ 17.61, as of March 31, 2024 and an average exchange rate of MYR 1 = ₹ 17.83 for the Financial Year ended March 31, 2024

Note:

(1) Revenue from operations also corresponds to the total sales generated during the relevant financial period/year

(2) Restated profit for the period/year also corresponds to the profit after tax for the relevant financial period/year

As on the date of this Draft Red Herring Prospectus, the shareholding pattern of Chemopharm Sdn. Bhd. is as follows:

Name of the shareholder	Number of ordinary shares having no par value	Percentage of shareholding (%)
Everlife Holdings Pte. Ltd.	5,929,099	100.00
Ooi Chuai Aun	1	Negligible
Total	5,929,100	100.00

Research Instruments Pte. Ltd.

Key financial information

Set forth below are key financial information of Research Instruments Pte. Ltd. for the three months period ended June 30, 2026 and the Financial Years ended March 31, 2026, March 31, 2025 and March 31, 2024:

(in ₹ million, unless otherwise stated)

Particulars	As at and for the three months period ended June 30, 2026 ⁽¹⁾	As at and for Financial Year ended March 31, 2026 ⁽²⁾	As at and for Financial Year ended March 31, 2025 ⁽³⁾	As at and for Financial Year ended March 31, 2024 ⁽⁴⁾
Equity share capital	146.11	145.96	25.54	24.74
Preference share capital	0.00	0.00	-	-
Revenue from operations	542.69	1,840.55	1,469.23	1,342.62
Other income	0.30	0.50	1.31	5.97
Total income	542.99	1,841.05	1,470.54	1,348.59
Restated profit for the period/year	73.86	217.63	165.80	200.38
Revenue from operations as a percentage of consolidated revenue (in %)	7.39	7.14	7.72	8.64
Reserves (excluding revaluation reserves)	338.10	301.35	322.72	304.92
Earnings per share (Basic)	36.93	235.07	414.50	500.96
Earnings per share (Diluted)	36.93	235.07	414.50	500.96
Total borrowings	137.23	124.28	174.54	164.93
Net worth	484.21	447.31	348.26	329.66
Net asset value	242.11	223.65	870.66	824.15

(1) Calculated basis the exchange rate of SGD 1 = ₹ 73.06, as of June 30, 2026 and an average exchange rate of SGD 1 = ₹ 73.95 for the three months period ended June 30, 2026

(2) Calculated basis the exchange rate of SGD 1 = ₹ 72.98 as of March 31, 2026 and an average exchange rate of SGD 1 = ₹ 68.53 for the Financial Year ended March 31, 2026

(3) Calculated basis the exchange rate of SGD 1 = ₹ 63.86 as of March 31, 2025 and an average exchange rate of SGD 1 = ₹ 63.17 for the Financial Year ended March 31, 2025

(4) Calculated basis the exchange rate of SGD 1 = ₹ 61.86, as of March 31, 2024 and an average exchange rate of SGD 1 = ₹ 61.56 for the Financial Year ended March 31, 2024

Note:

- (1) Revenue from operations also corresponds to the total sales generated during the relevant financial period/year
- (2) Restated profit for the period/year also corresponds to the profit after tax for the relevant financial period/year

As on the date of this Draft Red Herring Prospectus, the shareholding pattern of Research Instruments Pte. Ltd. is as follows:

Name of the shareholder	Number of ordinary shares of SGD 1 each	Percentage of shareholding (%)
Chemopharm Sdn. Bhd.	2,000,000	100.00
Total	2,000,000	100.00

As of the date of this Draft Red Herring Prospectus, except as set out below, none of our Subsidiaries whose outstanding borrowings are proposed to be repaid/prepaid from the Net Proceeds have obtained credit rating from any recognised rating agency, either in India or abroad:

Subsidiary	Instrument type	Date	Rating
CPC Diagnostics Private Limited	Long term fund based cash credit, term loan, overdraft facilities and long term unallocated limits	March 30, 2026	[ICRA]BBB+ (Stable): Reaffirmed
	Short term interchangeable limits		[ICRA] A2; Reaffirmed

The extent of the borrowings proposed to be prepaid and/or repaid as mentioned in the table above, is not determined and the repayment/ prepayment of the loans shall be based on various factors, including (i) any conditions attached to the borrowings restricting our ability to prepay the borrowings and time taken to fulfil such requirements, (ii) levy of any prepayment penalties and the quantum thereof, (iii) provisions of any law, rules, regulations governing such borrowings, and (iv) other commercial considerations including, among others, the interest rate on the loan facility, the amount of the loan outstanding and the remaining tenor of the loan. Prepayment penalty or premium, if any, and other related costs shall be made by us out of the Net Proceeds. Further, none of the borrowing have been availed from the related parties of our Company or been used for inter-group loans that could result in the indirect utilisation of the Net Proceeds for intra-group funding.

Our Company has obtained consents / no objection certificates, to the extent applicable, from the lenders whose borrowings are proposed to be repaid and/or prepaid by our Wholly Owned Subsidiaries and our Step-Down Subsidiaries.

Mode of Investment in the Wholly Owned Subsidiaries and the Step-Down Subsidiaries

Pursuant to the resolution of our Board dated October 19, 2026, our Company shall deploy the amount of Net Proceeds allocated towards the repayment of certain loans of the abovementioned Wholly Owned Subsidiaries and the abovementioned Step-Down Subsidiaries in the form of equity or debt investments, details of which are set forth below:

Investment by way of equity

Our Company shall deploy a portion of the Net Proceeds aggregating up to ₹ 3,655.90 million, in one or more tranches, by way of subscription of fully paid-up equity instruments in Everlife Holdings. The board of directors of Everlife Holdings, pursuant to its resolution dated October 18, 2026, has taken on record such investment.

1. Everlife Holdings shall thereafter utilise the amount to invest into the abovementioned Step-Down Subsidiaries, namely, Chemopharm Sdn. Bhd. and Research Instruments Pte. Ltd, by way of extending loan facilities/ debt investments, details of which set forth below:

Term	Particulars
------	-------------

Chemopharm Sdn. Bhd.	
Interest	5.82% p.a.
Security	Unsecured
Terms of repayment	Upon demand by Everlife Holding
Research Instruments Pte. Ltd	
Interest	3.00% p.a
Security	NA
Terms of repayment	Repayment within 60 months, unless mutually agreed to extend at the same terms

The board of directors of Everlife Holdings, pursuant to its resolution dated October 18, 2026 has authorised the deployment of ₹ 3,438.86 million into Chemopharm Sdn. Bhd. and ₹ 217.04 million into Research Instruments Pte. Ltd. through debt. Further, each of the boards of directors of Chemopharm Sdn. Bhd. and Research Instruments Pte. Ltd, pursuant to their resolutions dated October 18, 2026 and October 18, 2026, respectively, have approved the availing of loan facility(ies) from Everlife Holdings, where the funds from such loan facility(ies) shall be utilised for the purposes of repaying/prepaying certain of their borrowings.

- Our Company shall deploy a portion of the Net Proceeds aggregating up to ₹ 733.76 million and ₹ 204.98 million, respectively, in one or more tranches, by way of subscription of fully paid-up equity instruments in Translumina Therapeutics and Transhealth. The boards of directors of Translumina Therapeutics and Transhealth, pursuant to their resolutions dated October 17, 2026 and October 17, 2026, respectively, have passed an enabling resolution for the issuance of equity shares to our Company pursuant to the infusion of funds, where such funds shall be utilised for the purposes of repaying/prepaying certain of their borrowings.

Investment by way of debt

Our Company shall deploy a portion of the Net Proceeds aggregating up to ₹ 503.87 million, in one or more tranches, by way of extending loan facility/ debt investment in our Step-Down Subsidiaries, namely, CPC Diagnostics Private, details of which set forth below:

Term	Particulars
CPC Diagnostics Private Limited	
Interest	10% p.a.
Security	Unsecured
Terms of repayment	Repayment in give years from the date of disbursement of the first tranche, unless extended
Subordination	First priority over any other unsecured liabilities of CPC Diagnostics

The boards of directors of CPC Diagnostics, pursuant to its resolutions dated October 16, 2026, has passed an enabling resolution for availing loan facility (ies) from our Company, where the funds from such loan facility(ies) shall be utilised for the purposes of repaying/prepaying certain of their borrowings.

Further, for all investments by way of debt, it is clarified that the Company will recover the principal amount with applicable interest, in accordance with the terms and conditions of the investments, as detailed above, for applicable Wholly-Owned Subsidiaries and Step-Down Subsidiaries. Such amount will subsequently be used by the Company for business purposes in accordance with applicable laws, which will include the following working capital purposes, organic capital expenditure that the Company may undertake. Everlife Holdings, Translumina Therapeutics and Transhealth, do not have any stated dividend policy and our Company cannot be assured of any dividends from such investment. Our Company will remain interested in our Wholly Owned Subsidiaries and our Step-Down Subsidiaries to the extent of our shareholding (direct or indirect, as applicable), and as a lender to whom funds have been deployed by way of debt.

While ICICI Bank Limited (“**ICICI Bank**”) is an affiliate of ICICI Securities Limited, one of our BRLMs and Citibank N.A and Citi Bank Limited (collectively, “**Citibank**”) are affiliates of Citigroup Global Markets India Private Limited, also one of our BRLMs, ICICI Bank and Citibank are not associates of our Company, our Wholly Owned Subsidiaries or our Step-Down Subsidiaries, in terms of the Securities and Exchange Board of India (Merchant Bankers) Regulations, 1992 and such loans have been sanctioned to our Wholly Owned Subsidiaries and our Step-Down Subsidiaries (as applicable) as part of the normal commercial lending activity by ICICI Bank and Citibank. Accordingly, we do not believe that there is any conflict of interest under the Securities and Exchange Board of India (Merchant Bankers) Regulations, 1992, as amended, or any other applicable SEBI rules

or regulations. Please also see, “*Risk Factors – A portion of the Net Proceeds may be utilized for the repayment/prepayment, in full or in part, of certain outstanding borrowings availed by our certain Subsidiaries from lenders who are affiliates of our BRLMs.*” on page [●].

2. General corporate purposes

The Net Proceeds will first be utilized for the Object as set out above. Our Company intends to deploy any balance left out of the Net Proceeds towards general corporate purposes, as approved by our management, from time to time, subject to such utilization for general corporate purposes not exceeding 25% of the Gross Proceeds, in compliance with the SEBI ICDR Regulations.

Such general corporate purpose may include, but not limited to meeting expenses incurred in the ordinary course of business such as strategic initiatives, including growth opportunities, meeting expenses for research and development and meeting general corporate exigencies and contingencies and any other business requirements, along with any other purpose as may be approved by our Board or a duly appointed committee from time to time, subject to compliance with necessary provisions of the Companies Act, 2013.

The allocation or quantum of utilization of funds towards the specific purposes described above will also be determined by our Board, based on our business requirements and other relevant considerations, from time to time, subject to compliance with necessary provisions of the Companies Act, the SEBI ICDR Regulations, the SEBI Listing Regulations and other applicable laws. Our management, in accordance with the policies of the Board, shall have the flexibility in utilising surplus amounts, if any. In the event that our Company is unable to utilise the entire amount that our Company has currently estimated for use out of Net Proceeds in a given Fiscal, our Company will utilise such unutilised amount in the next Fiscal.

Interim use of Net Proceeds

Pending utilization of the Net Proceeds for the purposes described above, our Company undertakes to deposit the Net Proceeds only in one or more scheduled commercial banks included in the Second Schedule of the Reserve Bank of India Act, 1934, as amended, as may be approved by our Board. In accordance with Section 27 of the Companies Act, our Company confirms that it shall not use the Net Proceeds for buying, trading or otherwise dealing in shares of any other listed company or for any investment in the equity markets.

Appraising entity

None of the Objects require appraisal from, or have been appraised by, any bank/ financial institution/ any other agency, in accordance with applicable law.

Bridge financing

Our Company has not raised any bridge loans from any bank or financial institution as on the date of this Draft Red Herring Prospectus, which are proposed to be repaid from the Net Proceeds.

Offer expenses

The total Offer related expenses are estimated to be approximately ₹ [●] million.

Other than: (i) the listing fees and fees and expenses of the statutory auditors only in relation to the routine statutory audit of our Company entities and expenses for any product or corporate advertisements consistent with past practice of our Company (other than the expenses relating to marketing and advertisements in connection with the Offer), which will be borne solely by our Company (to the extent not attributable to the Offer); and (ii) fees and expenses for counsel to the Promoter Selling Shareholder, if any, which shall be borne solely and directly by the Promoter Selling Shareholder, the Promoter Selling Shareholder agrees, to share the costs and expenses (excluding all applicable taxes except STT, which shall be solely borne by the Promoter Selling Shareholder) directly attributable to the Offer, all Offer Expenses including, among other things, filing fees, book building fees and other charges, fees and expenses of the SEBI, the Stock Exchanges, the RoC and any other Governmental Authority, advertising, printing, road show expenses, accommodation and travel expenses, fees and expenses of the Indian legal counsel to our Company and the Indian and international legal counsel to the BRLMs, fees and expenses of the statutory auditors of our Company entities, registrar fees and broker fees (including fees for procuring of applications), bank charges, fees and expenses (and related taxes) of the BRLMs (also Members of the Syndicate) Self Certified Syndicate Banks, other Designated Intermediaries and any other consultant, advisor

or third party in connection with the Offer shall be borne by our Company and the Promoter Selling Shareholder in proportion to the number of Equity Shares proposed to be issued and Allotted by our Company through the Fresh Issue and the portion of Offered Shares proposed to be sold by the Promoter Selling Shareholder through the Offer for Sale, respectively, except as may be prescribed by the SEBI or any other regulatory authority.

In the event that the Offer is postponed or withdrawn or abandoned for any reason or the Offer is not successful or consummated, all costs and expenses with respect to the Offer which may have accrued up to the date of such postponement, withdrawal, abandonment or failure shall be shared amongst our Company and the Promoter Selling Shareholder, in proportion to the number of Equity Shares proposed to be issued and allotted by our Company in the Fresh Issue and the portion of Offered Shares proposed to be sold by the Promoter Selling Shareholder in the Offer for Sale, except as may be prescribed by the SEBI or any other regulatory authority. However, expenses relating to the Offer for Sale may be paid by our Company on behalf of the Promoter Selling Shareholder in the first instance and the Promoter Selling Shareholder agrees that upon commencement of listing and trading of the Equity Shares on the Stock Exchanges pursuant to the Offer, each Promoter Selling Shareholder shall, reimburse our Company for such expenses in relation to the Offer paid by our Company on behalf of the Promoter Selling Shareholder in proportion to the Offered Shares directly from the Public Offer Account in the manner as may be set out in the Cash Escrow and Sponsor Banks Agreement.

The break-up for the estimated Offer expenses are as follows:

Activity	Estimated expenses ⁽¹⁾ (₹ in million)	As a % of total estimated Offer related expenses ⁽¹⁾	As a % of Offer size ⁽¹⁾
BRLM's fees (including brokerage and selling commission)	[●]	[●]	[●]
Commission/processing fee for SCSBs, Sponsor Bank(s) and Bankers to the Offer. Brokerage and selling commission and bidding charges for Members of the Syndicate, Registered Brokers, RTAs and CDPs ⁽¹⁾⁽²⁾⁽³⁾	[●]	[●]	[●]
Fees payable to Registrar to the Offer	[●]	[●]	[●]
Fees payable to the other parties to the Offer, including, Statutory Auditors, Independent Chartered Accountant, industry expert, practicing company secretary, and independent chartered engineer	[●]	[●]	[●]
Advertising and marketing expenses for the Offer	[●]	[●]	[●]
Others	[●]	[●]	[●]
Listing fees, SEBI filing fees, upload fees, BSE and NSE processing fees, book building software fees and other regulatory expenses	[●]	[●]	[●]
Printing and stationery	[●]	[●]	[●]
Fees payable to legal counsel	[●]	[●]	[●]
Miscellaneous*	[●]	[●]	[●]
Total estimated Offer expenses	[●]	[●]	[●]

Offer expenses include applicable taxes, where applicable. Offer expenses will be finalised on determination of Offer Price and incorporated at the time of filing of the Prospectus. Offer expenses are estimates and are subject to change.

Selling commission payable to the SCSBs on the portion for RIBs and Non-Institutional Bidders which are directly procured and uploaded by the SCSBs, would be as follows:

Portion for RIBs*	[●]% of the Amount Allotted (plus applicable taxes)
Portion for Non-Institutional Bidders*	[●]% of the Amount Allotted (plus applicable taxes)

* Amount Allotted is the product of the number of Equity Shares Allotted and the Offer Price.

Selling Commission payable to the SCSBs will be determined on the basis of the bidding terminal id as captured in the Bid book of BSE or NSE.

No processing fees shall be payable by our Company and the Promoter Selling Shareholder to the SCSBs on the applications directly procured by them.

Processing fees payable to the SCSBs of ₹[●] per valid application (plus applicable taxes) for processing the Bid cum Application Form for Non-Institutional Bidders which are procured by the members of the Syndicate/sub-Syndicate/Registered Broker/RTAs/CDPs and submitted to SCSB for blocking.

Brokerage, selling commission and processing/uploading charges on the portion for RIBs (using the UPI mechanism) and Non-

Institutional Bidders which are procured by members of the Syndicate (including their sub-Syndicate Members), RTAs and CDPs or for using 3-in-1 type accounts- linked online trading, demat & bank account provided by some of the brokers which are members of Syndicate (including their sub-Syndicate Members) would be as follows:

Portion for RIBs	[●]% of the Amount Allotted (plus applicable taxes)
Portion for Non-Institutional Bidders	[●]% of the Amount Allotted (plus applicable taxes)

The Selling commission payable to the Syndicate / sub-Syndicate Members will be determined on the basis of the application form number / series, provided that the application is also bid by the respective Syndicate / sub-Syndicate Member. For clarification, if a Syndicate ASBA application on the application form number / series of a Syndicate / sub-Syndicate Member, is bid by an SCSB, the Selling Commission will be payable to the SCSB and not the Syndicate / sub-Syndicate Member.

In addition to the selling commission referred above, any additional amount(s) to be paid by our Company and the Promoter Selling Shareholder shall be as mutually agreed amongst the Book Running Lead Managers (also the Members of the Syndicate), our Company and the Promoter Selling Shareholder before the opening of the Offer.

Uploading Charges payable to members of the Syndicate (including their sub-Syndicate Members), RTAs and CDPs on the applications made by RIBs using 3-in-1 accounts/Syndicate ASBA mechanism and Non-Institutional Bidders which are procured by them and submitted to SCSB for blocking or using 3-in-1 accounts/Syndicate ASBA mechanism, would be as follows: ₹ 10 plus applicable taxes, per valid application bid by the Syndicate (including their sub-Syndicate Members), RTAs and CDPs.

The selling commission and bidding charges payable to Registered Brokers, the RTAs and CDPs will be determined on the basis of the bidding terminal id as captured in the Bid Book of BSE or NSE.

Selling commission/ uploading charges payable to the Registered Brokers on the portion for RIBs and Non-Institutional Bidders which are directly procured by the Registered Broker and submitted to SCSB for processing, would be as follows:

Portion for RIBs*	₹ [●] per valid application (plus applicable taxes)
Portion for Non-Institutional Bidders*	₹ [●] per valid application (plus applicable taxes)

Uploading charges/ Processing fees for applications made by RIBs using the UPI Mechanism would be as under:

Members of the Syndicate / RTAs / CDPs /Registered Brokers	₹ [●] per valid application (plus applicable taxes)
Sponsor Bank(s)	₹ [●] for applications made by UPI Bidders using the UPI mechanism*. The Sponsor Bank(s) shall be responsible for making payments to the third parties such as remitter bank, NPCI and such other parties as required in connection with the performance of its duties under the SEBI circulars, the Syndicate Agreement and other applicable laws.

** Based on valid applications*

All such commissions and processing fees set out above shall be paid as per the timelines in terms of the Syndicate Agreement and Cash Escrow and Sponsor Bank Agreement.

The processing fees for applications made by UPI Bidders using the UPI Mechanism may be released to the remitter banks (SCSBs) only after such banks provide a written confirmation on compliance with SEBI ICDR Master Circular.

Monitoring of utilisation of funds

In accordance with Regulation 41 of the SEBI ICDR Regulations, our Company shall appoint a Monitoring Agency for monitoring the utilisation of Gross Proceeds prior to the filing of the Red Herring Prospectus with the RoC, as the proposed Fresh Issue exceeds ₹ 1,000 million.

Our Audit Committee and the Monitoring Agency will monitor the utilisation of the Gross Proceeds and the Monitoring Agency shall submit the report required under Regulation 41(2) of the SEBI ICDR Regulations, on a quarterly basis, until such time as the Gross Proceeds have been utilised in full, which shall include item-by-item description for all the expense heads under each object of the Offer. Our Company undertakes to place the report(s) of the Monitoring Agency on receipt before the Audit Committee without any delay. Our Company will disclose and continue to disclose, the utilisation of the Gross Proceeds, including interim use under a separate head in our balance sheet for such Fiscals as required under applicable law, clearly specifying the purposes for which the Gross Proceeds have been utilised, till the time any part of the Gross Proceeds remains unutilised. Our Company will also, in its balance sheet for the applicable Fiscals, provide details, if any, in relation to all such Gross Proceeds that have not been utilised, if any, of such currently unutilised Gross Proceeds. Further, our Company, on a quarterly basis, shall include the deployment of Gross Proceeds under various expense heads, as applicable, in the notes to our quarterly consolidated results. Our Company will indicate investments, if any, of unutilised Gross Proceeds in the balance sheet of our Company for the relevant Fiscals subsequent to receipt of listing and trading approvals from the Stock Exchanges.

Pursuant to Regulation 32(3) and Part C of Schedule II, of the SEBI Listing Regulations, our Company shall, on a quarterly basis, disclose to the Audit Committee the uses and applications of the Gross Proceeds. The Audit Committee shall make recommendations to our Board for further action, if appropriate. The statement shall be certified by the Statutory Auditor of our Company. Furthermore, in accordance with Regulation 32(1) of the SEBI Listing Regulations, our Company shall furnish to the Stock Exchanges on a quarterly basis, a statement indicating category wise deviations/variations, if any, in the actual utilisation of the proceeds of the Gross Proceeds from the Objects as stated above. This information will also be published in newspapers simultaneously with the interim or annual financial results and explanation for such variation (if any) will be included in our Director's report, after placing the same before the Audit Committee.

Variation in Objects

In accordance with the Companies Act, our Company shall not vary the Objects without being authorised to do so by our Shareholders by way of a special resolution through a postal ballot. In addition, the notice issued to our Shareholders in relation to the passing of such special resolution (“**Postal Ballot Notice**”) shall specify the prescribed details as required under the Companies Act and applicable rules. The Postal Ballot Notice shall simultaneously be published in the newspapers, one in English, one in Hindi, which is also the regional language of the jurisdiction where our Registered Office is located. In accordance with the Companies Act, our Promoters will be required to provide an exit opportunity to the Shareholders who do not agree to such proposal to vary the objects, subject to the provisions of the Companies Act and in accordance with such terms and conditions, including in respect of pricing of the Equity Shares, in accordance with our Articles of Association, the Companies Act and the SEBI ICDR Regulations. For risks arising out of variation in Objects, please see “*Risk Factors - Any variation in the utilisation of the Net Proceeds would be subject to certain compliance requirements, including prior Shareholders’ approval. Further, our funding requirements and deployment of the Net Proceeds of the Offer are based on management estimates and have not been independently appraised. Our management will have broad discretion over the use of the Net Proceeds*” on page [●].

Other confirmations

The Promoter Selling Shareholder will receive the proceeds of the Offer for Sale. Except as disclosed in this section, no part of the Net Proceeds will be paid by our Company as consideration to our Promoters, the Promoter Group, our Directors, or our KMPs and members of the Senior Management.

There are no existing or anticipated transactions in relation to utilisation of Net Proceeds with our Promoters, the Promoter Group, Group Companies, our Directors, our KMPs and Senior Management.

Except for our Wholly-Owned Subsidiaries and our Step-Down Subsidiaries (each as defined for the purposes of this section) whose loans are proposed to be repaid/prepaid from a portion of the Net Proceeds, none of our Subsidiaries, Associates, Group Companies, as applicable, shall receive a part of or whole of the Net Proceeds directly or indirectly.

Our Company has neither entered into nor has planned to enter into arrangement/ agreements with our Promoters, members of the Promoter Group, Directors, our Key Managerial Personnel, our Senior Management or our Group Companies in relation to the utilization of the Net Proceeds.

DECLARATION

I hereby certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, or guidelines, or regulations issued by the Government of India or the rules, or guidelines, or regulations issued by the Securities and Exchange Board of India, established under section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with and no statement made in this Addendum is contrary to the provisions of the Companies Act, 2013, the Securities Contracts (Regulation) Act, 1956, the Securities Contracts (Regulation) Rules, 1957, the Securities and Exchange Board of India Act, 1992, or the rules made or the guidelines or regulations issued thereunder, as the case may be. I further certify that all statements in this Addendum are true and correct.

SIGNED BY THE DIRECTOR OF OUR COMPANY

Annaswamy Vaidheesh

Chairperson and Non-Executive Independent Director

Date: October 19, 2026

Place: Mumbai

DECLARATION

I hereby certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, or guidelines, or regulations issued by the Government of India or the rules, or guidelines, or regulations issued by the Securities and Exchange Board of India, established under section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with and no statement made in this Addendum is contrary to the provisions of the Companies Act, 2013, the Securities Contracts (Regulation) Act, 1956, the Securities Contracts (Regulation) Rules, 1957, the Securities and Exchange Board of India Act, 1992, or the rules made or the guidelines or regulations issued thereunder, as the case may be. I further certify that all statements in this Addendum are true and correct.

SIGNED BY THE DIRECTOR OF OUR COMPANY

Rajani Kesari

Non- Executive Independent Director

Date: October 19, 2026

Place: Mumbai

DECLARATION

I hereby certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, or guidelines, or regulations issued by the Government of India or the rules, or guidelines, or regulations issued by the Securities and Exchange Board of India, established under section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with and no statement made in this Addendum is contrary to the provisions of the Companies Act, 2013, the Securities Contracts (Regulation) Act, 1956, the Securities Contracts (Regulation) Rules, 1957, the Securities and Exchange Board of India Act, 1992, or the rules made or the guidelines or regulations issued thereunder, as the case may be. I further certify that all statements in this Addendum are true and correct.

SIGNED BY THE DIRECTOR OF OUR COMPANY

Ramesh Subrahmanian

Non- Executive Independent Director

Date: October 19, 2026

Place: Singapore

DECLARATION

I hereby certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, or guidelines, or regulations issued by the Government of India or the rules, or guidelines, or regulations issued by the Securities and Exchange Board of India, established under section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with and no statement made in this Addendum is contrary to the provisions of the Companies Act, 2013, the Securities Contracts (Regulation) Act, 1956, the Securities Contracts (Regulation) Rules, 1957, the Securities and Exchange Board of India Act, 1992, or the rules made or the guidelines or regulations issued thereunder, as the case may be. I further certify that all statements in this Addendum are true and correct.

SIGNED BY THE DIRECTOR OF OUR COMPANY

Gurmit Singh Chugh

Non-Executive Director

Date: October 19, 2026

Place: Delhi

DECLARATION

I hereby certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, or guidelines, or regulations issued by the Government of India or the rules, or guidelines, or regulations issued by the Securities and Exchange Board of India, established under section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with and no statement made in this Addendum is contrary to the provisions of the Companies Act, 2013, the Securities Contracts (Regulation) Act, 1956, the Securities Contracts (Regulation) Rules, 1957, the Securities and Exchange Board of India Act, 1992, or the rules made or the guidelines or regulations issued thereunder, as the case may be. I further certify that all statements in this Addendum are true and correct.

SIGNED BY THE DIRECTOR OF OUR COMPANY

Avnish Mehra

Non-Executive Nominee Director

Date: October 19, 2026

Place: Singapore

DECLARATION

I hereby certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, or guidelines, or regulations issued by the Government of India or the rules, or guidelines, or regulations issued by the Securities and Exchange Board of India, established under section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with and no statement made in this Addendum is contrary to the provisions of the Companies Act, 2013, the Securities Contracts (Regulation) Act, 1956, the Securities Contracts (Regulation) Rules, 1957, the Securities and Exchange Board of India Act, 1992, or the rules made or the guidelines or regulations issued thereunder, as the case may be. I further certify that all statements in this Addendum are true and correct.

SIGNED BY THE DIRECTOR OF OUR COMPANY

Punita Sharma

Non-Executive Director

Date: October 19, 2026

Place: Delhi

DECLARATION

I hereby certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, or guidelines, or regulations issued by the Government of India or the rules, or guidelines, or regulations issued by the Securities and Exchange Board of India, established under section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with and no statement made in this Addendum is contrary to the provisions of the Companies Act, 2013, the Securities Contracts (Regulation) Act, 1956, the Securities Contracts (Regulation) Rules, 1957, the Securities and Exchange Board of India Act, 1992, or the rules made or the guidelines or regulations issued thereunder, as the case may be. I further certify that all statements in this Addendum are true and correct.

SIGNED BY THE DIRECTOR OF OUR COMPANY

Arjun Oberoi

Non-Executive Nominee Director

Date: October 19, 2026

Place: Shanghai

DECLARATION

I hereby certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, or guidelines, or regulations issued by the Government of India or the rules, or guidelines, or regulations issued by the Securities and Exchange Board of India, established under section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with and no statement made in this Addendum is contrary to the provisions of the Companies Act, 2013, the Securities Contracts (Regulation) Act, 1956, the Securities Contracts (Regulation) Rules, 1957, the Securities and Exchange Board of India Act, 1992, or the rules made or the guidelines or regulations issued thereunder, as the case may be. I further certify that all statements in this Addendum are true and correct.

SIGNED BY THE DIRECTOR OF OUR COMPANY

Probir Das

Executive Director and Group Chief Executive Officer

Date: October 19, 2026

Place: Kolkata

DECLARATION

I hereby certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, or guidelines, or regulations issued by the Government of India or the rules, or guidelines, or regulations issued by the Securities and Exchange Board of India, established under section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with and no statement made in this Addendum is contrary to the provisions of the Companies Act, 2013, the Securities Contracts (Regulation) Act, 1956, the Securities Contracts (Regulation) Rules, 1957, the Securities and Exchange Board of India Act, 1992, or the rules made or the guidelines or regulations issued thereunder, as the case may be. I further certify that all statements in this Addendum are true and correct.

SIGNED BY THE DIRECTOR OF OUR COMPANY

Vishal Omprakash Goenka

Non-Executive Nominee Director

Date: October 19, 2026

Place: Mumbai

DECLARATION

I hereby certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, or guidelines, or regulations issued by the Government of India or the rules, or guidelines, or regulations issued by the Securities and Exchange Board of India, established under section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with and no statement made in this Addendum is contrary to the provisions of the Companies Act, 2013, the Securities Contracts (Regulation) Act, 1956, the Securities Contracts (Regulation) Rules, 1957, the Securities and Exchange Board of India Act, 1992, or the rules made or the guidelines or regulations issued thereunder, as the case may be. I further certify that all statements in this Addendum are true and correct.

SIGNED BY THE CHIEF FINANCIAL OFFICER OF OUR COMPANY

Dev Kumar Tripathy

Date: October 19, 2026

Place: Gurugram

DECLARATION

We, Evercure Holdings Pte. Ltd., the Promoter Selling Shareholder, hereby confirm, certify and declare that all statements and undertakings specifically made or confirmed by us in this Addendum in relation to ourselves, as the Promoter Selling Shareholder and the Offered Shares, are true and correct. We assume no responsibility, for any other statements, disclosures and undertakings, including, any of the statements, disclosures or undertakings made or confirmed by or relating to the Company or any other person(s) in this Addendum.

Signed for an on behalf of Evercure Holdings Pte. Ltd.

Name: Terence Gerard Gomes

Designation: Director

Date: October 19, 2026

Place: Singapore